A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 4074
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : QALYs
Long Form : quality-adjusted life years
No. Year Title Co-occurring Abbreviation
1983 Measuring elusive benefits: on the value of health. ---
1986 Performance indicators and performance assessment in the UK National Health Service: implications for management and planning. DRGs
1987 Incentives for cost-effective physician behavior. ---
1987 Measuring the effectiveness of heart transplant programmes: quality of life data and their relationship to survival analysis. NHP
1988 A cost-effectiveness analysis of exercise as a health promotion activity. CHD
1988 Should QALYs be programme-specific? ---
1989 Castigating QALYs. ---
1989 Choosing who shall not be treated in the NHS. ---
1989 The benefits of treating mild to moderate hypertension. A quantitative estimation of the life expectancy gains from pharmacological reduction of blood pressure. ---
10  1989 The use of QALYS (quality-adjusted life years) in health service planning. RHA
11  1989 The use of QALYs in health care decision making. ---
12  1989 Utilities and quality-adjusted life years. ---
13  1990 Quality of life--economic aspects. ---
14  1990 Should treatment of mild to moderate hypertension be targeted? Results from a Markov cohort model incorporating multiple risk factors. ---
15  1990 The use of quality-adjusted life years (QALYs) in the economic appraisal of health care. ---
16  1990 Treating mild to moderate hypertension: cost-effectiveness and policy implications. DBP
17  1991 Chiropody and the QALY: a case study in assigning categories of disability and distress to patients. ---
18  1991 Measuring the adverse effects of unnecessary hypertension drug therapy: QALYs vs HYE. ABP, HYE
19  1991 QALYs and the equity-efficiency trade-off. ---
20  1991 The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. ---
21  1991 The costs and benefits of bone marrow transplantation. BMT
22  1991 The principle of QALY maximisation as the basis for allocating health care resources. ---
23  1992 Measuring outcome of total knee replacement using quality of life indices. ---
24  1992 Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). HYE, HYEs, QALY
25  1992 Reprocessing data to form QALYs. ---
26  1992 The value of health care: what can we learn from Oregon? ---
27  1992 Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. CNVAF
28  1993 Appraising the use of contingent valuation: a note in response. CV, HYEs
29  1993 Determining patient utility following coronary revascularization. ---
30  1993 QALYs (Quality Adjusted Life Years): a nurse's view. ---
31  1993 QALYs for resource allocation: probably not and certainly not now. ---
32  1993 Selection of end points in economic evaluations of coronary-heart-disease interventions. CHD
33  1993 The QALY: a guide for the public health physician. ---
34  1994 An introduction to clinical microeconomic analysis: purposes and analytic methods. ---
35  1994 Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. A cost and quality-of-life evaluation. HMQ
36  1994 Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. ---
37  1994 Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. ---
38  1994 Effect of isotretinoin on the quality of life of patients with acne. ---
39  1994 Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. HRT
40  1994 Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. ---
41  1994 Pros and cons for using quality-adjusted life years (QALYs) ---
42  1994 QALYs, HYEs and individual preferences--a graphical illustration. HYEs
43  1994 Quality adjusted life years added by treatment of obstructive sleep apnea. nCPAP, OSA
44  1994 Should hepatitis C-infected kidneys be transplanted in the United States? HCV
45  1994 The cost-effectiveness of early surgery versus watchful waiting in the management of small abdominal aortic aneurysms. AAAs
46  1994 The standard gamble method: what is being measured and how it is interpreted. HYE, SG, vNM
47  1995 Elective surgery for asymptomatic, unruptured, intracranial aneurysms: a cost-effectiveness analysis. ---
48  1995 Evaluating health services: the importance of patients' preferences and quality of life. ---
49  1995 Historical and methodological perspectives on cancer outcomes research. ---
50  1995 Modelling the cost effectiveness of antidepressant treatment in primary care. ---
51  1995 Referral for coronary angiography after exercise testing: traditional decision-making versus decision analysis. ---
52  1995 Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. ---
53  1995 Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. CVI
54  1995 The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. EA-HYEs, EXP-HYEs, HYEs, RA-QALYs, RN-QALYs
55  1995 The use of "quality-adjusted life years" (QALYs) to evaluate treatment in intensive care. dQALYs, ICU
56  1995 The use of condition specific outcome measures in economic appraisal. CSOMs
57  1996 A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. QALE, THA
58  1996 Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. ---
59  1996 Cost-utility analysis of home parenteral nutrition. HPN
60  1996 Palliative care and the ethics of resource allocation. ---
61  1996 Preferences, needs and QALYs. ---
62  1996 Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. TSH
63  1996 The prostate: decreasing cost-effectiveness of biopsy with advancing age. PSA
64  1996 Treatment costs in Hodgkin's disease: a cost-utility analysis. HD
65  1996 [Quality adjusted life years in assessment of preventive measures. Should blood donors be tested for HTLV-I/II infections?]. ---
66  1997 A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. ATL
67  1997 An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening. ---
68  1997 Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. DVT, PTS
69  1997 Avoiding double-counting in pharmacoeconomic studies. ---
70  1997 Constructing health state preference values from descriptive quality of life outcomes: mission impossible? HSPVs
71  1997 Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. ---
72  1997 Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. ---
73  1997 Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. CMV
74  1997 Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. CUAs
75  1997 Drug treatments for maintaining remission in Crohn's disease. A lifetime cost-utility analysis. QOL
76  1997 Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. AAA, AIOD, CS, CSR, PRBCs
77  1997 Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model. ---
78  1997 Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. ---
79  1997 Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. RS, SG, TTO
80  1997 The cost-effectiveness of a cardiovascular risk reduction program in general practice. CVD
81  1997 The cost-effectiveness of air bags by seating position. ---
82  1997 The importance of perspective in the measurement of quality-adjusted life years. ---
83  1997 The Quality of Well-Being scale in asymptomatic HIV-infected patients. HNRC Group. HIV Neural Behavioral Research Center. HIV, HNRC, QWB, UCSD
84  1997 The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. ---
85  1997 Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. ---
86  1997 [Analysis of prolonged intensive care after abdominal surgery interventions with special reference to quality of life and economy]. GLQI
87  1997 [Cost-effectiveness analysis of the screening strategies for primary angle closure glaucoma]. AACD, PACD, PACG
88  1997 [Prolonged intensive care stay after abdominal surgery interventions with special reference to quality of life, occupational rehabilitation and economics]. ---
89  1998 A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture. ---
90  1998 Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. ---
91  1998 Assessing the benefits of testing for breast cancer susceptibility genes: a decision analysis. ---
92  1998 Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. ---
93  1998 Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. ---
94  1998 Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. ---
95  1998 Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. HCFA, SEER
96  1998 Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. QWB, SF-36
97  1998 Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents. ---
98  1998 Endoscopic versus open carpal tunnel release: a cost-effectiveness analysis. ---
99  1998 Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. ---
100  1998 The effectiveness of cost-effectiveness analysis in containing costs. CE, CEAs
101  1998 The measurement of individual utility and social welfare. ---
102  1998 The Quality of Well-Being Scale: critical similarities and differences with SF-36. QWB, SF-36
103  1998 Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model. HSRA
104  1998 Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. ASR
105  1998 Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. WTP
106  1999 Age-related preferences and age weighting health benefits. ---
107  1999 Analysis of the Cost-effectiveness of Photodynamic Therapy in Early Stage Lung Cancer. PDT
108  1999 Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. ---
109  1999 Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. PET, SPECT
110  1999 Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. ---
111  1999 Evidence-based medicine, utilities, and quality of life. ---
112  1999 Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. ---
113  1999 Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. BPH, TURP
114  1999 Health-related quality of life of Colles' fracture patients. HRQoL, NOF, VAS
115  1999 How to get serious answers to the serious question: "How have you been?": subjective quality of life (QOL) as an individual experiential emergent construct. ACSA, QOL
116  1999 Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. ---
117  1999 Inconsistent responses in three preference-elicitation methods for health states. ---
118  1999 Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. HD
119  1999 Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? ---
120  1999 Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. ---
121  1999 Probability Weighting and Utility Curvature in QALY-Based Decision Making. ---
122  1999 Public involvement in health care priority setting: an economic perspective. ---
123  1999 Should endovascular surgery lower the threshold for repair of abdominal aortic aneurysms? AAAs
124  1999 Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. IL, mRCC
125  1999 The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. ---
126  1999 The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. ---
127  1999 The use of CT scanning in dementia. A systematic review. CT
128  1999 Which unruptured cerebral aneurysms should be treated? A cost-utility analysis. CI, SAH
129  1999 Willingness to pay and the valuation of programmes for the prevention and control of influenza. WTP
130  1999 [Common effect measures in medical and health economics studies? Results of an exploratory survey of physicians]. HRQoL
131  2000 A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. GERD, H2RAs, PPIs
132  2000 A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. ---
133  2000 Antiviral therapies for herpes zoster infections. Are they economically justifiable? PHN
134  2000 Are QALYs an appropriate measure for valuing morbidity in acute diseases? ---
135  2000 Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. BMT, CBV, PBT, SCD
136  2000 Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. ---
137  2000 Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. ---
138  2000 Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. ---
139  2000 Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer. EBB, TRT
140  2000 Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. DES, LHRH, NSAA
141  2000 Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. VT
142  2000 Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery. ABD, CABG, CE
143  2000 Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. MR, SPECT
144  2000 Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. ---
145  2000 Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. SPMS
146  2000 Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. ---
147  2000 Economic evaluation of HIV risk reduction intervention in African-American male adolescents. ---
148  2000 Has the impact of hormone replacement therapy on health-related quality of life been undervalued? HRT, QWB, U-Titer
149  2000 Health outcome measures used in cost-effectiveness studies: a review of original articles published between 1986 and 1996. CEA, CUA, HEED
150  2000 HIV transmission and the cost-effectiveness of methadone maintenance. ---
151  2000 Improving value measurement in cost-effectiveness analysis. CEA
152  2000 Income effects of reduced health and health effects of reduced income: implications for health-state valuation. ---
153  2000 Income-related inequality in life-years and quality-adjusted life-years. ---
154  2000 Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness. IVUS, RCTs
155  2000 Mammography screening for older women with and without cognitive impairment. ---
156  2000 Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. ---
157  2000 Screening for Type 2 diabetes mellitus: a decision analytic approach. ---
158  2000 Systematic overview of cost-utility assessments in oncology. CUAs
159  2000 The quality of reporting in published cost-utility analyses, 1976-1997. ---
160  2000 To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. ACE, ESRF
161  2000 Understanding quality-adjusted life years and their application to pharmacoeconomic research. CEA, HRQoL
162  2000 [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium]. ---
163  2000 [Organ shortage in transplant centers--approaches to a solution from the economic viewpoint]. ---
164  2001 A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. DM
165  2001 A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. ---
166  2001 A UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. CI, NHS, TMLR
167  2001 Assessing the cost-effectiveness of HAART for adults with HIV in England. HAART, NRTIs
168  2001 Assessment of clinical guidelines for continuation treatment in major depression. TWD
169  2001 Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. ---
170  2001 Cost utility of public clinics to increase pneumococcal vaccines in the elderly. ---
171  2001 Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. ---
172  2001 Cost-effectiveness of a school-based tobacco-use prevention program. LYs, TNT
173  2001 Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. ---
174  2001 Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men. CBO
175  2001 Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. UI
176  2001 Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. CHD, NHANES III
177  2001 Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomized clinical trial. ---
178  2001 Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. NINDS, tPA
179  2001 Decision analysis for small, asymptomatic intracranial arteriovenous malformations. AVMs
180  2001 Developing appropriate measures of the benefits of complementary and alternative medicine. CAM, CEAs
181  2001 Dynamic modeling in medical technology assessment. Fitting hearing aids in The Netherlands. ---
182  2001 Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. OLS
183  2001 Evaluation of the QALY model for analysis of cost-effectiveness of eating training after stroke. EQALYs
184  2001 Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. CER
185  2001 Impact of hip and vertebral fractures on quality-adjusted life years. ---
186  2001 Improvement in quality of life from photodynamic therapy: a Canadian perspective. CNV, TAP
187  2001 Improving estimates of caregiver time cost and family impact associated with birth defects. ---
188  2001 Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis. BMA
189  2001 Investigating women's preferences for intrapartum care: home versus hospital births. ---
190  2001 Methylphenidate in children with hyperactivity: review and cost-utility analysis. ---
191  2001 On individual preferences and aggregation in economic evaluation in healthcare. CBA, CEA/CUA, WTP
192  2001 Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. PTC
193  2001 Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. ---
194  2001 Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ICDs
195  2001 Public health impact of changes in smoking behavior: results from the Tobacco Policy Model. ---
196  2001 Quality adjusted life years (QALYs) and dose-response models in environmental health policy analysis -- methodological considerations. QALY
197  2001 Quality-adjusted survival in the first year after the acute respiratory distress syndrome. ARDS, QWB
198  2001 Simulated effect of tobacco tax variation on Latino health in California. ---
199  2001 Simulated effect of tobacco tax variation on population health in California. CI
200  2001 The 15D instrument of health-related quality of life: properties and applications. HRQoL, NHP
201  2001 The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. ---
202  2001 The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. ---
203  2001 The cost-effectiveness of neonatal surgery and subsequent treatment for congenital anorectal malformations. CAM
204  2001 The cost-utility of screening for depression in primary care. ---
205  2001 The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. PHN
206  2001 Theory versus practice: a review of 'willingness-to-pay' in health and health care. WTP
207  2001 [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks]. ---
208  2002 A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. HUI3, OA, WOMAC
209  2002 Abdominal aortic aneurysms: cost-effectiveness of elective endovascular and open surgical repair. AAAs, CER
210  2002 An economic evaluation of early versus delayed operative treatment in patients with closed tibial shaft fractures. ---
211  2002 Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. AIPRI
212  2002 Automated current health time-trade-off assessments in women's health. SF-36, TTO, VAS
213  2002 Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. GI
214  2002 Condom distribution: a cost-utility analysis. ---
215  2002 Cost and effectiveness of hip protectors among the elderly. ---
216  2002 Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. DVT, LMWH, UFH
217  2002 Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. PD
218  2002 Cost-effectiveness analysis and emergency medical services for children: issues and applications. CEA
219  2002 Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. IFNB, NHS
220  2002 Cost-effectiveness and cost-utility of long-term management strategies for heartburn. CEACs
221  2002 Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. ASCUS, HPV, YLS
222  2002 Cost-effectiveness of cadaveric and living-donor liver transplantation. ESLD, OLT
223  2002 Cost-effectiveness of gastric bypass for severe obesity. ---
224  2002 Cost-effectiveness of preventive occupational therapy for independent-living older adults. OT
225  2002 Cost-effectiveness of prophylactic indomethacin in very-low-birth-weight infants. IVH, PDA, RCTs
226  2002 Cost-utility analysis of patient care in children with meningeal signs. ---
227  2002 Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. ---
228  2002 Costs and benefits of carotid endarterectomy and associated preoperative arterial imaging: a systematic review of health economic literature. CEA
229  2002 Development of an economic model to assess the cost effectiveness of asthma management strategies. FP, SFC
230  2002 Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? ---
231  2002 Economic evaluation of MARS--preliminary results on survival and quality of life. ---
232  2002 Estimating an EQ-5D population value set: the case of Japan. MAE
233  2002 Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. QOL
234  2002 Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease. CCOHTA, ICURs
235  2002 Funding the new biologics--public policy issues in drug formulary decision making. ---
236  2002 HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. DALYs, HALYs
237  2002 Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome. CPAP, SAHS, Usg
238  2002 Healthy-year equivalents in major joint replacement. Can patients provide meaningful responses? HYEs, WOMAC
239  2002 Impact of the U.S. panel on cost-effectiveness in health and medicine. ---
240  2002 Incremental cost-effectiveness of initial cataract surgery. PORT
241  2002 Measuring the social importance of concentration or dispersion of individual health benefits. ---
242  2002 Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. HAQ, RA
243  2002 Optimal allocation of resources across four interventions for type 2 diabetes. ---
244  2002 Paraesophageal hernias: operation or observation? ELHR, WW
245  2002 Preference-based outcome measures in cost-utility analyses. A 20-year overview. HYEs
246  2002 QALY-maximisation and public preferences: results from a general population survey. ---
247  2002 QALYs versus WTP. WTP
248  2002 Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. DVT, LMWH, PTS, THRS, VTE
249  2002 Routine duplex surveillance does not improve the outcome after carotid endarterectomy: a decision and cost utility analysis. ---
250  2002 Selecting human health metrics for environmental decision-support tools. DALYs, WTP
251  2002 State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. ADAP, QALY
252  2002 Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation. DES
253  2002 The cost utility of bisphosphonate treatment in established osteoporosis. ---
254  2002 The cost-effectiveness of treatment for congenital diaphragmatic hernia. CDH
255  2002 The importance of lowering the costs of stem cell transplantation in developing countries. HRQL
256  2002 The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. BPO, IPSS, LUTS, TTO
257  2002 Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. HCV, HIV
258  2003 A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients. ICER, LR, OM, ONM
259  2003 A cost-utility analysis of patients undergoing orthognathic treatment for the management of dentofacial disharmony. TTO
260  2003 A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. ---
261  2003 A test of the QALY model when health varies over time. ---
262  2003 A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. ---
263  2003 An empirical comparison of EQ-5D and SF-6D in liver transplant patients. ---
264  2003 Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. ICH
265  2003 Cost-benefit approach in evaluating investment into donor action: the German case. CCUs, DA, DR, pmp
266  2003 Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. AUG
267  2003 Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. ---
268  2003 Cost-effectiveness of a primary care depression intervention. ---
269  2003 Cost-effectiveness of a primary care intervention for depressed females. ---
270  2003 Cost-effectiveness of a targeted disinfection program in household kitchens to prevent foodborne illnesses in the United States, Canada, and the United Kingdom. ---
271  2003 Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. FDG, PET
272  2003 Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. BARI
273  2003 Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in The Netherlands. CE, DSA, MRA
274  2003 Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics. STD
275  2003 Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. COX-2, NSAIDs, RA
276  2003 Cost-effectiveness of PET in the diagnosis of Alzheimer disease. AD, MR, PET, SPECT
277  2003 Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. HGD, ICERs, PDT, QALE
278  2003 Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. rhAPC
279  2003 Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. HCV
280  2003 Cost-effectiveness of use of the GlucoWatch Biographer in children and adolescents with type 1 diabetes: a preliminary analysis based on a randomized controlled trial. DCCT, YOL
281  2003 Cost-effectiveness targets for multi-detector row CT angiography in the work-up of patients with intermittent claudication. CT, MR
282  2003 Cost-utility analysis comparing free and pedicled TRAM flap for breast reconstruction. ICUR
283  2003 Cost-utility analysis of cataract surgery in the second eye. ---
284  2003 Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. CML
285  2003 Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. IVIG
286  2003 Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. ---
287  2003 Double discounting of QALYs. TTO
288  2003 Economic analysis of a school-based obesity prevention program. ---
289  2003 Economic evaluation of breast cancer treatment: considering the value of patient choice. ---
290  2003 Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. ITI
291  2003 Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. ---
292  2003 Fuels for urban transit buses: a cost-effectiveness analysis. CD, CE, CNG, ECD, PM
293  2003 Health care economic analyses and value-based medicine. ---
294  2003 How to identify and assess tasks and challenges of Medical Image Processing. MIP, MRMIP
295  2003 Impact of particulate air pollution on quality-adjusted life expectancy in Canada. ACS
296  2003 Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. ---
297  2003 Living renal donors: optimizing the imaging strategy--decision- and cost-effectiveness analysis. CT, DSA, MR
298  2003 Management of influenza symptoms in healthy adults. ---
299  2003 Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. ILI
300  2003 Pharmacoeconomic analysis of osteoporosis treatment with risedronate. ---
301  2003 Pretreatment imaging workup for patients with intermittent claudication: a cost-effectiveness analysis. CE, DSA, MR, US
302  2003 Problems and solutions in calculating quality-adjusted life years (QALYs). QALY
303  2003 Regional variation in the cost effectiveness of childhood hepatitis A immunization. ---
304  2003 Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. ---
305  2003 The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. CSII, MDI, SD
306  2003 The impact of including passive benefits in cost-effectiveness analysis: the case of automated external defibrillators on commercial aircraft. ---
307  2003 The validity of time trade-off values in calculating QALYs: constant proportional time trade-off versus the proportional heuristic. CPTTO, MET, TTO
308  2003 The value of the change in health in Sweden 1980/81 to 1996/97. ---
309  2003 Treatment of pulmonary arterial hypertension: a preliminary decision analysis. PAH, QOL
310  2003 Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. AML, BMT, CT, MSD
311  2003 Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism? WTP
312  2003 Variation in the estimation of quality-adjusted life-years by different preference-based instruments. SF-6D
313  2003 When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. AAN, AD, PET
314  2003 [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]. CML, IFN
315  2003 [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]. ---
316  2004 A cost-effectiveness analysis of bacterial endocarditis prophylaxis for febrile children who have cardiac lesions and undergo urinary catheterization in the emergency department. BE, UC
317  2004 A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. CCHT, QOL
318  2004 A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. EBL, MED, OR, TIPS, VH
319  2004 A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. CMV
320  2004 A new and more robust test of QALYs. ---
321  2004 Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQoL-5D. BI, HRQoL
322  2004 Benefits and harms associated with hormone replacement therapy: clinical decision analysis. HRT
323  2004 Body mass index and quality of well-being in a community of older adults. BMI, HRQoL, QWB
324  2004 Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. RCTs
325  2004 Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. CAPRIE
326  2004 Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. QALY
327  2004 Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. ADCS-ADL
328  2004 Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. MORE, SEK
329  2004 Cost-effectiveness analysis of telemedicine to evaluate diabetic retinopathy in a prison population. ---
330  2004 Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. ---
331  2004 Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. ---
332  2004 Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. PTC, SR, TM
333  2004 Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. ---
334  2004 Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. CML
335  2004 Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. COPD
336  2004 Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. HBV, HCV, HIV, NAT, SS, US
337  2004 Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives. ---
338  2004 Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. HIV, PEP
339  2004 Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. ---
340  2004 Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. ---
341  2004 Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. BNP, EF
342  2004 Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. ---
343  2004 Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? ---
344  2004 Cost-utility analysis in evaluating prophylaxis in haemophilia. CUA, HRQoL, QOL
345  2004 Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. CML
346  2004 Costs and net health effects of contraceptive methods. ---
347  2004 Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults II: cost-effectiveness analysis. ---
348  2004 Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. ECT, rTMS
349  2004 Does early imaging influence management and improve outcome in patients with low back pain? A pragmatic randomised controlled trial. LBP
350  2004 Economic analysis of VenUS I, a randomized trial of two bandages for treating venous leg ulcers. CI, NHS
351  2004 Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease. COPD, HRQoL
352  2004 Economic evaluation of treatments for cancer in childhood. ---
353  2004 Elective cesarean delivery to prevent perinatal transmission of hepatitis C virus: a cost-effectiveness analysis. HCV
354  2004 Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. HRQL, SF-36
355  2004 EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy. AH, LH, VH
356  2004 HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. FISH, ICER
357  2004 Imaging of carotid arteries in symptomatic patients: cost-effectiveness of diagnostic strategies. DSA, MR, TIA, US
358  2004 Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. CT
359  2004 Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. anti-TNF, HRQoL, HUI3, RA
360  2004 Management for severe Crohn's disease: a lifetime cost-utility analysis. ---
361  2004 Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. ICERs, TNF
362  2004 Patient-reported outcome in total hip replacement. A comparison of five instruments of health status. OHS, THR, WOMAC
363  2004 Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. ---
364  2004 Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. ---
365  2004 Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. ATDs, RAI
366  2004 Regionalization of treatment for subarachnoid hemorrhage: a cost-utility analysis. SAH
367  2004 Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. TTO
368  2004 Should the donor radius be plated prophylactically after harvest of a radial osteocutaneous flap? A cost-effectiveness analysis. ---
369  2004 Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis. WOMAC
370  2004 The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). AS
371  2004 The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. CRC
372  2004 The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. FGA, MCO, OTC, PMPM, SGA
373  2004 The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling. EA, HMB, MEA, RB, TBEA, TCRE, TCRE
374  2004 The use of probabilistic decision models in technology assessment : the case of total hip replacement. CI
375  2004 United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. UK BEAM
376  2004 What is the best imaging strategy for acute stroke? CT, PICH
377  2004 Yield of screening for new aneurysms after treatment for subarachnoid hemorrhage. CTA, SAH
378  2004 [Cost-utility analysis; uncertainties restrict applicability]. ---
379  2005 A cost-effectiveness analysis of a hypothetical catheter-based strategy for the detection and treatment of vulnerable coronary plaques with drug-eluting stents. ---
380  2005 A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ---
381  2005 A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention. LIPS, MACEs, SD
382  2005 A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer. SHE
383  2005 A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. YLS
384  2005 A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. HAD-D, SSRIs, TCAs
385  2005 A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. BMD, CHD, RCTs
386  2005 An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. ACR, ACR70, CEAs, DAS, DMARDs, HAQ, HRQoL, ICERs, RA, TNF
387  2005 Analysis of aspirin-associated risks in healthy individuals. ---
388  2005 Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? EQ-5D, HAQ, RA, RAQoL, SF-6D
389  2005 Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. ADHD, HRQL, SG
390  2005 Axioms for health care resource allocation. ---
391  2005 Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation. USRDS
392  2005 Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. DI, HAQ, RA, TNF
393  2005 Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. COMPANION, CRT, ICERs, OPT
394  2005 Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. CI, LIFE, LVH, MI, QOL, VAS
395  2005 Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). UKATT
396  2005 Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. ---
397  2005 Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. C/E, COX-2, GI, NSAIDs, PPI, RA
398  2005 Cost-effectiveness and safety of epidural steroids in the management of sciatica. ESIs, NICE, ODQ
399  2005 Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments. ---
400  2005 Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity. CER
401  2005 Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. CLO, DP/A, DSPM, PBO
402  2005 Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy. CE-MRA, DSA, DUS
403  2005 Cost-effectiveness of endovascular abdominal aortic aneurysm repair. AAA, EVAR, ICER
404  2005 Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention. LIPS, LYs, MACE, PCI
405  2005 Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. ACE
406  2005 Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. CLT, HCC, LDLT
407  2005 Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. DDCI, ICER, LCE, NHS, PD
408  2005 Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. ---
409  2005 Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. LMWH, PE, UFH
410  2005 Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. SEK
411  2005 Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. i.v, NHS, SREs
412  2005 Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. NNT
413  2005 Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. BCS, DCIS, ICER, INV, NINV, NSABP, RT
414  2005 Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. MORE
415  2005 Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. ICU, RBC, rHuEPO
416  2005 Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. CHOP, DLBCL, ICER
417  2005 Cost-effectiveness of screening for deep vein thrombosis by ultrasound at admission to stroke rehabilitation. DVT
418  2005 Cost-effectiveness of single-level anterior cervical discectomy and fusion for cervical spondylosis. ACDF, ACDFP, CEA
419  2005 Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis. HAQ, MACTAR, RA, SF-6D, VAS
420  2005 Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. M-ECT, MDD, MPT
421  2005 Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ---
422  2005 Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). RT, RTOG
423  2005 Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting. GPs, ICER, SENSE
424  2005 Economic evaluation of proton radiation therapy in the treatment of breast cancer. ---
425  2005 Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. ---
426  2005 Estimating the health impacts of tobacco harm reduction policies: a simulation modeling approach. ---
427  2005 Estimating utility data from clinical indicators for patients with stable angina. CCS, HRQL
428  2005 Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. NRT
429  2005 Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. HD, RRT
430  2005 Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. ASI, BCG
431  2005 Impact of adhesive capsulitis and economic evaluation of high-grade and low-grade mobilisation techniques. SF-6D
432  2005 Increasing socio-economic inequalities in life expectancy and QALYs in Sweden 1980-1997. ---
433  2005 Is expanding Medicare coverage cost-effective? ---
434  2005 Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. HRQoL, JIA, land
435  2005 Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation. NICE, RCTs, TAPP, TEP
436  2005 Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. ---
437  2005 Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. AIMS, HAQ, HDC, HSCT, RA, SF-36, TRM
438  2005 Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? GPAs, NSTE-ACS
439  2005 Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. RA
440  2005 One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention. ---
441  2005 Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. ---
442  2005 Orlistat for the treatment of obesity: cost utility model. EMEA, NICE
443  2005 Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. ICERs
444  2005 Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding. ART, BF, ICER, NVP
445  2005 Proton therapy of cancer: potential clinical advantages and cost-effectiveness. ---
446  2005 QALY maximisation and people's preferences: a methodological review of the literature. ---
447  2005 Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey. PCNV, VAS, WTP
448  2005 Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. ---
449  2005 Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. HRT, WHI
450  2005 Responsiveness of generic health-related quality of life measures in stroke. CES-D, EQ-VAS, HRQoL, HUI, MRS
451  2005 Screening for congenital cataracts: a cost-consequence analysis of eye examination at maternity wards in comparison to well-baby clinics. ---
452  2005 Screening to prevent polyoma virus nephropathy: a medical decision analysis. PVN
453  2005 Some Ethical Corrections to Valuing Health Programs in Terms of Quality-Adjusted Life Years (QALYs). ---
454  2005 Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial. SD 0.431
455  2005 The AMA proposal to mandate nicotine reduction in cigarettes: a simulation of the population health impacts. AMA
456  2005 The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. BROSG, DMARD, HAQ, OSRA, RA
457  2005 The cost effectiveness of health insurance. ---
458  2005 The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach. ICER
459  2005 The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. SCOPE
460  2005 The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. DPP
461  2005 The cost-effectiveness of raising the legal smoking age in California. ---
462  2005 The development of a preference-based measure of health in children with atopic dermatitis. AD, HUI 2
463  2005 The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. ---
464  2005 Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris. PMR
465  2005 Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. ---
466  2005 Using value of information analysis to inform publicly funded research priorities. NCCHTA, NHS, UTIs, VUR
467  2005 [Discussion of relationship between quality of life and clinical effect assessment of malignant tumor treated with traditional Chinese medicine]. QOL, TCM
468  2005 [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness]. CRT
469  2006 A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. ICERs, RCTs
470  2006 A cost effectiveness analysis within a randomised controlled trial of post-acute care of older people in a community hospital. ---
471  2006 A cost-utility analysis of hysterectomy, endometrial resection and ablation and medical therapy for menorrhagia. ICER, LNG-IUS
472  2006 A cost-utility analysis of open and endoscopic carpal tunnel release. ECTR, ICUR, OCTR
473  2006 A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. ---
474  2006 A pattern-mixture model for the analysis of censored quality-of-life data. QOL
475  2006 A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. BPAR, BSA, BSAp, BTAS, CAS, CAS, CMS, GFR, ICER, MMF, MPS, RCT, TAS
476  2006 Accurate, practical and cost-effective assessment of carotid stenosis in the UK. CE-MRA, CI, CTA, IAA, MRA, STARD, TIA, US
477  2006 An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. DPP
478  2006 An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial. CI, ICUs, PACs
479  2006 An unadjusted NNT was a moderately good predictor of health benefit. NNT, ROC
480  2006 Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. DAS28, EQ-5D, HAQ, ICC, RA, TTO
481  2006 Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. CUA, QOL, RCTs
482  2006 Calculating QALYs, comparing QALY and DALY calculations. DALYs
483  2006 Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations? HP, ICER
484  2006 Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. HAART, HIV
485  2006 Comprehensive cost-utility analysis of newborn screening strategies. ---
486  2006 Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. CT, SEER
487  2006 Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. CTSs, HBV, STD
488  2006 Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. ---
489  2006 Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. BSC, EPO, MDS
490  2006 Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. ICERs, RA, TNF-alpha
491  2006 Cost utility for penetrating keratoplasty in patients with poor binocular vision. PK
492  2006 Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient. HIT, HITT, VTE
493  2006 Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. CVD, ESRD
494  2006 Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. CR, CT, HD
495  2006 Cost-effectiveness analysis of open colposuspension versus laparoscopic colposuspension in the treatment of urodynamic stress incontinence. CrI, ICER
496  2006 Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. ICD, ICER, MTWA
497  2006 Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. DSA, PSA
498  2006 Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. CORE, HbA1c, NPH
499  2006 Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. ADE, ARVs, ENF, OB
500  2006 Cost-effectiveness of hospital pay-for-performance incentives. ---
501  2006 Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model. SCLC
502  2006 Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. ASO, HRQoL
503  2006 Cost-effectiveness of pediatric heart transplantation. ---
504  2006 Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. IFN/RBV
505  2006 Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. HbA1c
506  2006 Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany. ---
507  2006 Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CI
508  2006 Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia. ---
509  2006 Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. ---
510  2006 Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. SMBG, UKPDS
511  2006 Cost-utility analysis of routine neurosurgical spinal surgery. HRQoL
512  2006 Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. CI
513  2006 Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. PD
514  2006 Costs and quality of life in multiple sclerosis in The Netherlands. EDSS, MS, QOL
515  2006 Costs of the standard rheumatology care in active rheumatoid arthritis patients seen in a tertiary care center in Mexico City. RA
516  2006 Decision analysis in aerospace medicine: costs and benefits of a hyperbaric facility in space. DCS, HBO, ISS, NASA
517  2006 Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? INFLX, TC/IPAA
518  2006 Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. CAS, ICER, TKR
519  2006 Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. ---
520  2006 Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. PTH
521  2006 Economic evaluation of tandem mass spectrometry screening in California. MS/MS
522  2006 Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? RVGE
523  2006 Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. IDUs
524  2006 Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. DMARDs, PsA, TNF
525  2006 Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. CI, COPD, FP, TORCH
526  2006 Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement. HY, PD
527  2006 Evaluation of the ventricular assist device programme in the UK. HRQoL, ICERs, ICU, VAD
528  2006 Hearing-impaired children in the United Kingdom, IV: cost-effectiveness of pediatric cochlear implantation. ---
529  2006 Implantable or external defibrillators for individuals at increased risk of cardiac arrest: where cost-effectiveness hits fiscal reality. AEDs, EMS-D, ICDs
530  2006 Incremental cost-effectiveness of a collaborative care intervention for panic disorder. AFDs, CBT, CI
531  2006 Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs. AIPC, LH-RHas
532  2006 Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. ---
533  2006 Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease. IBD
534  2006 Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. ---
535  2006 Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. LTAD, RTOG, STAD
536  2006 Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. ICU, QOL, SOFA
537  2006 Model to assess the cost-effectiveness of new treatments for depression. ---
538  2006 Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. ACR20, DMARDs, HAQ, MTX, RA, SSZ, TNF
539  2006 Modelling the costs and consequences of treating paediatric faecal impaction in Australia. ---
540  2006 Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK. AF
541  2006 One-year cost-effectiveness of surgical treatment of morbid obesity: vertical banded gastroplasty versus Lap-Band. VBG
542  2006 Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. PSM
543  2006 Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. EXE, LET, LYG, TAM
544  2006 Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? GI, NSAIDs, PPIs
545  2006 Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: a cost-effectiveness analysis. ICE, IQR, PTM, RA, TTM
546  2006 Randomized clinical trial comparing surgery with conservative treatment for uncomplicated varicose veins. CI, EQ, SF
547  2006 Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: cost-effectiveness analysis. CI, GPs
548  2006 Rapid benefit-risk assessments: no escape from expert judgments in risk management. ---
549  2006 Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. ---
550  2006 Retrospective cost-effectiveness analysis of screening mammography. ---
551  2006 Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. ACR, DMARDs, ICER, RA, TNF-a
552  2006 Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. CR
553  2006 Shunts in normal-pressure hydrocephalus: do we place too many or too few? NPH
554  2006 Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. ACO, EVPI, GORD, HGD, RCTs
555  2006 The benefits and risks of bacille Calmette-Guerin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model. ARI, BCG, SCID, TB
556  2006 The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. ICER
557  2006 The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia. ICER
558  2006 The cost utility of strabismus surgery in adults. ---
559  2006 The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. BD-I
560  2006 The cost-effectiveness of screening for oral cancer in primary care. EVPI, ICERs
561  2006 The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. CHC, PNALT
562  2006 The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis. HNHD, IHD
563  2006 The PEX study - Exercise therapy for patellofemoral pain syndrome: design of a randomized clinical trial in general practice and sports medicine [ISRCTN83938749]. PFPS
564  2006 The role of disease burden measures in future estimates of endemic waterborne disease. DALYs
565  2006 Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. HRQoL
566  2006 Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. IMRT
567  2006 Utility of surgery for ruptured abdominal aortic aneurysm. QOL, rAAA
568  2006 Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies. CBDS, ERCP, MRCP
569  2006 Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? HSMs, QWB, WTP
570  2006 When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. HAART, ICER
571  2006 [Health economics of psychological diseases]. ---
572  2006 [How are quality-adjusted life years defined in German studies?]. ---
573  2006 [Quality of life and utility measures: clinical parameters for decision-making in health]. ---
574  2007 A brief pain management program compared with physical therapy for low back pain: results from an economic analysis alongside a randomized clinical trial. BPM, PT
575  2007 A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma. EUS, EUS/FNA, PTP
576  2007 A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. AT, ICER
577  2007 A cost-effectiveness analysis of alcohol prevention targeting licensed premises. ---
578  2007 A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. ---
579  2007 A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. ICER
580  2007 A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. mHRPC
581  2007 A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. PDT
582  2007 Abnormal outcomes following cervical cancer screening: event duration and health utility loss. CIN
583  2007 Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model. CA125
584  2007 Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. ---
585  2007 Composite tissue allotransplantation of the face: Decision analysis model. ---
586  2007 Cost effectiveness and cost utility of an organized screening programme for glaucoma. ---
587  2007 Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. AS, ICER, OASIS
588  2007 Cost effectiveness of adjuvant interferon in node-positive melanoma. HDI, ICERs
589  2007 Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. HER2, HERA
590  2007 Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. GIST
591  2007 Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. ART, CHD, PI, QALM
592  2007 Cost effectiveness of mammography screening for Chinese women. ICER, LYS
593  2007 Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. AD, SGAs
594  2007 Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. EBC, ICER
595  2007 Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. DPN, GBP, ICER, NeP, PGB, PHN
596  2007 Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom. NHS, PHN, TCAs
597  2007 Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. HAART, WHO
598  2007 Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. HPA, NAIT
599  2007 Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. BASKET, ICERs
600  2007 Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. ---
601  2007 Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial. CAD, CI, MRI, SPECT
602  2007 Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. ---
603  2007 Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. SIT
604  2007 Cost-effectiveness of influenza vaccination in working-age cancer patients. SEER
605  2007 Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. ICUR
606  2007 Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. AD
607  2007 Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. ---
608  2007 Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. ICER
609  2007 Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. AMD, PDT, VYGs
610  2007 Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. HBV
611  2007 Cost-effectiveness of Spa treatment for fibromyalgia: general health improvement is not for free. CIs, FM, ICER, SF-6D, VAS
612  2007 Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. IES
613  2007 Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. BDP, NHS, TCF
614  2007 Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. ICERs, LYG
615  2007 Cost-effectiveness of vitamin therapy for age-related macular degeneration. AMD
616  2007 Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. HIV, IPT, TB, TST
617  2007 Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen. SES
618  2007 Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. BT, EB, PSA, RP, WW
619  2007 Depression-free day to utility-weighted score: is it valid? BDI, DFDs, QWB-SA
620  2007 Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. CT, EUS, US
621  2007 Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care. CE
622  2007 Drug-eluting stents: a systematic review and economic evaluation. BMS, CI, DES, MI, PCI, RCTs, TLR, TVR
623  2007 Economic consequences of alternative medication strategies in first episode non-affective psychosis. ---
624  2007 Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain. ESCAPE-knee pain, WTP
625  2007 Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS). BIC, CAB, CMA, CUA, CYP, HTs, INHS, PC, QuABIOS
626  2007 Economic evaluation of sevelamer in patients with end-stage renal disease. ---
627  2007 Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia. CLL, FCR, PHARMAC
628  2007 Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. CCHRT, CEE, MPA
629  2007 Effectiveness and cost-effectiveness of three types of physiotherapy used to reduce chronic low back pain disability: a pragmatic randomized trial with economic evaluation. ---
630  2007 Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. CDC-IRDs, HCV, HIV, IDUs, NAT
631  2007 Estimating health utilities and quality adjusted life years in seasonal affective disorder research. SAD
632  2007 Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. ---
633  2007 Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. ---
634  2007 Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. CVD
635  2007 Falls and health status in elderly women following first eye cataract surgery: an economic evaluation conducted alongside a randomised controlled trial. CI
636  2007 Health-related quality of life after stroke: review of the literature and implications for future research. CEA, DALYs, HAYLs
637  2007 Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. HRQoL, ICDs, MADIT II
638  2007 Impact of psychiatric disorders on health-related quality of life: general population survey. HRQoL
639  2007 Impact of selected risk factors on quality-adjusted life expectancy in Denmark. ---
640  2007 Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. ACS, CAD
641  2007 Influence of intraoperative conversion from off-pump to on-pump coronary artery bypass grafting on costs and quality of life: a cost-effectiveness analysis. CABG, OPCAB
642  2007 Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. AMI
643  2007 ISSLS prize winner: cost-effectiveness of two forms of circumferential lumbar fusion: a prospective randomized controlled trial. FRA, NHS, SF-6D, TC
644  2007 Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. HCM, ICD, SCD
645  2007 Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. ER, ICER, OROS
646  2007 Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children. ---
647  2007 Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. COPD, NHS, WTP
648  2007 NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD). ADHD, NICE
649  2007 Not all "quality-adjusted life years" are equal. EQ-5D, MTX, SF-6D
650  2007 Operative strategies for diverticular peritonitis: a decision analysis between primary resection and anastomosis versus Hartmann's procedures. HP, PADS, PRA
651  2007 Paternity leave in Sweden: costs, savings and health gains. ---
652  2007 Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. CI, HCV, INMB, VA
653  2007 Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis. BE, ESO, HGD, LYs, PDT, SURV, WTP
654  2007 Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. LDL-C
655  2007 Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. GBS
656  2007 PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. CEA, ICER, PROactive, QALE
657  2007 Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internet. ---
658  2007 QALY: an ethical issue that dare not speak its name. DALY
659  2007 Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. ---
660  2007 Randomized trial of two physiotherapy interventions for primary care back and neck pain patients: cost effectiveness analysis. ---
661  2007 Rights, responsibilities and NICE: a rejoinder to Harris. NHS, NICE
662  2007 Rotator cuff repair: an analysis of utility scores and cost-effectiveness. EuroQoL, HUI
663  2007 Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. ASA
664  2007 Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. EHT, H2RA, NSAIDs, PPIs, PU, SRH, UGI
665  2007 The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. BDI-II, BPRS, ECT, HRSD, RCT, rTMS, VAMS
666  2007 The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. CRT, CRT-D, ICERs, NICE, NYHA, OPT, SCD, WTP
667  2007 The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. CI, RR
668  2007 The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. ART, CD4, CI, ICER, TLC, VL
669  2007 The cost-effectiveness of a school-based overweight program. CATCH, CER, NB, NHANES, NHIS
670  2007 The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. BSR, DMARDs, HAQ, ICER, NHS, PsA, RA, TNF
671  2007 The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. CC, ESRD, LC
672  2007 The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. IVC, LN, MMF, QOL, SLE
673  2007 The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. RVR
674  2007 The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review. DES, QOL, TVR
675  2007 The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. CEAC, CI, HR, ICER, MGMT, PFS, RCTs, TMZ
676  2007 The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. ESRD, ICER, PTH, RCTs, SHPT
677  2007 The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration. ARMD
678  2007 The health-related quality-of-life impact of chronic conditions varied with age in general population. HRQoL
679  2007 The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. CC, GW, HPV
680  2007 The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. AMI, COPD, QBM
681  2007 The societal burden of osteoporosis in Sweden. ---
682  2007 The treatment of disabling intermittent claudication in patients with superficial femoral artery occlusive disease--decision analysis. GSVB, PTA/S, SFA, TASC
683  2007 Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. NPH
684  2007 Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study. UAE
685  2007 [Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam]. CE, ICER, LEV, PGB, ST
686  2007 [Economic evaluation of a new treatment for rheumatoid arthritis]. DALYs
687  2007 [The burden of depressive disorders in Germany - results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)]. EQ-5D, ESEMeD, HRQL, TTO
688  2008 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. CI, ICERs, NRT, RCTs
689  2008 A comparison of the superficial inferior epigastric artery flap and deep inferior epigastric perforator flap in postmastectomy reconstruction: A cost-effectiveness analysis. DIEP, ICUR, SIEA
690  2008 A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. ICER
691  2008 A cost-effectiveness analysis of delayed sphincteroplasty for anal sphincter injury. DS, ICER, PS, QOL
692  2008 A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. HAV
693  2008 A cost-utility analysis in patients receiving enteral tube feeding at home and in nursing homes. CVA, ETF
694  2008 A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. NHS, OAB
695  2008 A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. ESRD
696  2008 A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. ICER, IFX, SMT, UC
697  2008 A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study. CI, UAE
698  2008 A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. AMD, ARM
699  2008 A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. ---
700  2008 A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip. RCTs, THR, WMD
701  2008 A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. AMD
702  2008 A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery. ERM
703  2008 An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. NHS, NSCLC
704  2008 An economic evaluation of sevelamer in patients new to dialysis. ICERs
705  2008 An economic evaluation of the expanded food and nutrition education program. ---
706  2008 An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. BOV, LYG
707  2008 An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. HD, PD
708  2008 An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. PRP
709  2008 Assessing the influence of gestalt-type characteristics on preferences over lifetime health profiles. ---
710  2008 Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. BMS, DES, PCI, QALE, VLST
711  2008 Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. ---
712  2008 Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. INITIATE, QALE, SEK
713  2008 Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter? QWB, TTO
714  2008 Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). NSCLC
715  2008 Converting condition-specific measures into preference-based outcomes for use in economic evaluation. ---
716  2008 Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model. H. pylori, ICER, UBT
717  2008 Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial. CRT
718  2008 Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. ---
719  2008 Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. CVD, LDL-C
720  2008 Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. BCG, QFT, TST, TST/QFT
721  2008 Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis. aCCP, ACR, HAQ, ICER, RA, UA
722  2008 Cost effectiveness of the Expert Patients Programme (EPP) for patients with chronic conditions. CDSMP, EPP
723  2008 Cost-effective osteoporosis treatment thresholds: the United States perspective. RR
724  2008 Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. CINV, MEC
725  2008 Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. ICERs, UBT
726  2008 Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. ICER
727  2008 Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: the case of Sweden. EPO, EPO, RBCT
728  2008 Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. DFU, HBOT, LEAs
729  2008 Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. EVPI
730  2008 Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. BMI
731  2008 Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. SF
732  2008 Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. UFT
733  2008 Cost-effectiveness of automated telephone self-management support with nurse care management among patients with diabetes. ATSM
734  2008 Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. HPV, HPV-16,18
735  2008 Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. CLARITY, CREDO, CURE, PCI
736  2008 Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. COPD, CT
737  2008 Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. ACS, SOC
738  2008 Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. CVD, PTH, SHPT
739  2008 Cost-effectiveness of endarterectomy in patients with asymptomatic carotid artery stenosis. ACST
740  2008 Cost-effectiveness of HIV screening in patients older than 55 years of age. ---
741  2008 Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. QALE
742  2008 Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: results of a randomized controlled clinical trial. EPMROM, ICERs, IET, MACTAR, UC, VAS
743  2008 Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. HCTZ
744  2008 Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. BCG, LTBI, TST
745  2008 Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK. CI, GP, NHS
746  2008 Cost-effectiveness of magnetic resonance imaging of the knee for patients presenting in primary care. CI, MRI
747  2008 Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease. ABI, CAD, ICER, NHB, PAD
748  2008 Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. PCPT
749  2008 Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. AMD, PDT, VA
750  2008 Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. ---
751  2008 Cost-effectiveness of reducing wait times for cataract surgery in Ontario. ---
752  2008 Cost-effectiveness of smoking cessation to prevent age-related macular degeneration. ---
753  2008 Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. ICERs
754  2008 Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. BHI, BIAsp 30, CNY
755  2008 Cost-effectiveness of the Australian National Tobacco Campaign. AMI, COPD, NTC, QBM
756  2008 Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. HCC, ICER
757  2008 Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. ICER
758  2008 Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. MADRS
759  2008 Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. ARB, CCB, CHD, SBP
760  2008 Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. ICT
761  2008 Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand. ICER, rHuEPO
762  2008 Cost-utility analysis of rimonabant in the treatment of obesity. CHD, ICUR
763  2008 Cost-utility of a visiting service for older widowed individuals: randomised trial. CAU, ICUR
764  2008 Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial. ---
765  2008 Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial. ---
766  2008 Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia, and at what cost? A randomised controlled trial. BECCA, BF, HADS
767  2008 Economic and health consequences of managing bradycardia with dual-chamber compared to single-chamber ventricular pacemakers in Italy. ---
768  2008 Economic aspects of a therapy and support service for people with long-term stroke and aphasia. NHS
769  2008 Economic evaluation of a neural tube defect recurrence-prevention program. NTD
770  2008 Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. ---
771  2008 Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. ---
772  2008 Economic evaluation of human papillomavirus vaccination in the United Kingdom. ---
773  2008 Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. FVIII, KA, TKR
774  2008 Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. AEs, BSC, IL-2, LYs, mRCC
775  2008 Effect of nasal continuous positive airway pressure therapy on health-related quality of life in sleep apnoea patients treated in the routine clinical setting of a university hospital. HRQoL, nCPAP, OSAS
776  2008 Effectiveness and cost-effectiveness of height-screening programmes during the primary school years: a systematic review. ---
777  2008 Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage. SAH
778  2008 Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure. ICD
779  2008 Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. CVD
780  2008 Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. CHB
781  2008 Evaluating health care programs by combining cost with quality of life measures: a case study comparing capitation and fee for service. CEA, CMHC, DC, FFS, MBHO
782  2008 Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. NPH, OADs
783  2008 HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. CHB, HBeAg, ICERs, NTD
784  2008 HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. HCV, IDUs, IWSs
785  2008 Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. CD
786  2008 How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. PHPT
787  2008 Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. BrumEE, CHD, CLD, ICERs, LYG, RCTs, RSV
788  2008 Incorporating feelings related to the uncertainty about future health in utility measurement. HYEs, SG, SSUF
789  2008 Incorporation of process preferences within the QALY framework: a study of alternative methods. ---
790  2008 Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. ---
791  2008 Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness analysis. CITB, CP
792  2008 Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. ADHD, ICER, IR, OROS
793  2008 Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery. BT, QOL
794  2008 Longterm impact of abdominal decompression: a prospective comparative analysis. ACS, IAH
795  2008 Low back pain deprives the Japanese adult population of their quality of life: a questionnaire survey at five healthcare facilities in Japan. IDA, LBP, QOL
796  2008 Measurement of clinical-effect: utility. HUI, SG, TTO, VAS
797  2008 Measuring and valuing mental health for use in economic evaluation. ---
798  2008 Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme. ---
799  2008 Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm. CI, EVAR
800  2008 Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. CYC, SLS, SSc-ILD
801  2008 Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. CDM, ICERs, OADs, SD, T2DM, TZD
802  2008 Predictors of patient preferences and treatment choices for localized prostate cancer. ED
803  2008 Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial. ---
804  2008 Quality-adjusted life years lost from nonfatal motor vehicle accident injuries. MEPS
805  2008 Quantification of risk-benefit in interventional radiology. LET
806  2008 Quantitative risk-benefit analysis of natalizumab. MS, PML
807  2008 Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. ATEAM
808  2008 Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: a decision analysis model based on a systematic review. ---
809  2008 Responsiveness of EQ-5D utility indices in alcohol-dependent patients. ES
810  2008 Screening for abdominal aortic aneurysms in men: a Canadian perspective using Monte Carlo-based estimates. AAA, CI, US
811  2008 Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. HRQoL, rFVIIa, TTO, VAS
812  2008 Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states. ICERs, OAD, SMBG, T2DM
813  2008 Sixty-four-slice computed tomography of the coronary arteries: cost-effectiveness analysis of patients presenting to the emergency department with low-risk chest pain. CAD, CI, ECG, ED, ICERs, MDCT, OU, SD
814  2008 Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids: a systematic review and economic evaluation. CH, CI, OR, RCTs, SH
815  2008 Structural neuroimaging in psychosis: a systematic review and economic evaluation. CT, MRI
816  2008 Surgical strategies for faecal incontinence--a decision analysis between dynamic graciloplasty, artificial bowel sphincter and end stoma. ABS, DG, ES, FI, ICER, QOL
817  2008 The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents. NICE
818  2008 The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. NSTE-ACS
819  2008 The cost-effectiveness of atypicals in the UK. DES, NICE, PANSS
820  2008 The cost-effectiveness of thrombolysis administered by paramedics. ---
821  2008 The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. HD, SD, UC
822  2008 The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. ---
823  2008 The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. EQ-5D, GORD, SF-36
824  2008 The long-term cost-effectiveness of fetal monitoring during labour: a comparison of cardiotocography complemented with ST analysis versus cardiotocography alone. CTG, ICER
825  2008 The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. HPV, RRP
826  2008 The responsiveness of EQ-5D utility scores in patients with depression: A comparison with instruments measuring quality of life, psychopathology and social functioning. EQ VAS, ES
827  2008 The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. CI, PBAC
828  2008 The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis. LNF, PPIs, SFMs
829  2008 Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. ---
830  2008 Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. BIAsp 30, HI, SAR
831  2008 Total wrist arthroplasty and total wrist arthrodesis in rheumatoid arthritis: a decision analysis from the hand surgeons' perspective. RA
832  2008 Treatment of ruptured intracranial aneurysms: a decision analysis. SAH
833  2008 UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. HAQ, ICERs, RA, REFLEX
834  2008 [An economic assessment of genetic testing for familial adenomatous polyposis]. FAP
835  2008 [Assessment of health related quality of life--Part 1--Direct measures]. SG, TTO, VAS
836  2008 [Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel]. ARBs, DN, ESRD
837  2009 A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. SMR
838  2009 A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. CSII, ESRD, ICER, MDI, NNT, PDR, PVD, T1DM
839  2009 A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. ICERs
840  2009 A cost-effectiveness model comparing endovascular repair to open surgical repair of abdominal aortic aneurysms in Canada. AAAs, EVAR, OR
841  2009 A cost-utility analysis of nursing intervention via telephone follow-up for injured road users. ---
842  2009 A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. aOR, OME, OR
843  2009 A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. ---
844  2009 A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. ---
845  2009 A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial. EQ-5D, RCT, SF-6D
846  2009 Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. DDLT, ICER, LDLT
847  2009 An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. PSA, UC, UCDAI
848  2009 An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. OD, UC
849  2009 An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors. ACE, post-MI, VALIANT
850  2009 An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. NHS, QALE, RHI
851  2009 Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. CHB, HBV, HCC, ICERs
852  2009 Befriending carers of people with dementia: a cost utility analysis. BF, ICER
853  2009 Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. ICER, PE
854  2009 Benefit of carotid endarterectomy for symptomatic and asymptomatic severe carotid artery stenosis: a Markov model based on data from randomized controlled trials. Clinical article. CEA
855  2009 Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. MBC
856  2009 Breastfeeding promotion for infants in neonatal units: a systematic review and economic analysis. CI, NEC, OR, RR
857  2009 Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. CKD, LYG, SHPT, VDRA
858  2009 Clinical benefit and cost effectiveness of total knee arthroplasty in the older patient. MCER, TKA
859  2009 Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. CAD, CCTA
860  2009 Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. CD, CZP, EQ-5D, HRQoL, IBDQ, PRO, SF-36, VAS
861  2009 Comparing cost-utility estimates: does the choice of EQ-5D or SF-6D matter? ICER
862  2009 Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. EQ-5D, TTO, VAS
863  2009 Composite measures for hospital quality using quality-adjusted life years. CABG
864  2009 Computed tomographic coronary angiography for diagnosing stable coronary artery disease: a cost-utility and cost-effectiveness analysis. CAD, CAG, CTCA, ICER
865  2009 Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. MRI, XM
866  2009 Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. ---
867  2009 Cost effectiveness of open versus laparoscopic living-donor nephrectomy. LLDN
868  2009 Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. ---
869  2009 Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. ---
870  2009 Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees. ---
871  2009 Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. SCCHN
872  2009 Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. ASTs, ICERs
873  2009 Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA). CBT, MIND-DIA CEA, SH, TAU
874  2009 Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. BCG, T1G3
875  2009 Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. BCR, LTCFs, NPV
876  2009 Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. CHD, TC
877  2009 Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. ICER
878  2009 Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. BDI, CT, DFDs, MDD, REBT
879  2009 Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. ---
880  2009 Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. ---
881  2009 Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. ---
882  2009 Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care. PEP, UC
883  2009 Cost-effectiveness of accelerated perioperative care and rehabilitation after total hip and knee arthroplasty. ---
884  2009 Cost-effectiveness of an opportunistic screening programme and brief intervention for excessive alcohol use in primary care. CDM, SBI
885  2009 Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. ---
886  2009 Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. CD, ICERs
887  2009 Cost-Effectiveness Of Catheter Ablation Treatment For Patients With Symptomatic Atrial Fibrillation. AAD, RFA
888  2009 Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. ICER
889  2009 Cost-effectiveness of diabetes self-management programs in community primary care settings. ---
890  2009 Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. BMS, PES
891  2009 Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. ---
892  2009 Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury. ALI, LPV
893  2009 Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. GP, NHS
894  2009 Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. HTML, ICERs, NPH, T1DM, T2DM
895  2009 Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. TNT, UK
896  2009 Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada. CHD, CV
897  2009 Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. HCWs, IGRAs, LTBI, QFT-G, QFT-GIT, TSTs
898  2009 Cost-effectiveness of lifestyle modification in diabetic patients. ---
899  2009 Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids. MRgFUS, UAE
900  2009 Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. ICER, MR, PLND
901  2009 Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. MRI
902  2009 Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. HCL, NHS
903  2009 Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. ICER, PROactive
904  2009 Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. ---
905  2009 Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. AAD, AF, RFCA
906  2009 Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. COPD, SFC, TORCH, WTP
907  2009 Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. AUD
908  2009 Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. BIAsp 30, HI, KRW
909  2009 Cost-effectiveness of testing for breast cancer susceptibility genes. ---
910  2009 Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. QALE, TKA
911  2009 Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. ASCOT-BPLA, ICER, SBP
912  2009 Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. ---
913  2009 Cost-effectiveness of voluntary HIV screening in Russia. ---
914  2009 Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. LYGs, RSV
915  2009 Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. RA
916  2009 Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. PAH
917  2009 Costing and perspective in published cost-effectiveness analysis. CEAs
918  2009 Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. DES, HAQ, RA, SSATG, TNF-alpha
919  2009 CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. CAD, CT, ICERs
920  2009 Economic appraisal of the Boston Ocular Surface Prosthesis. ---
921  2009 Economic evaluation of a minimal psychological intervention in chronically ill elderly patients with minor or mild to moderate depression: a randomized trial (the DELTA-study). MPI
922  2009 Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. ---
923  2009 Economic evaluation of arthritis self management in primary care. ---
924  2009 Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. SPARCL, TIA
925  2009 Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial. MI
926  2009 Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. COX2, CV, DMARDs, GI, ICER, NSAIDs, PPIs
927  2009 Economic evaluation of systemic therapies for moderate to severe psoriasis. ICERs, PASI
928  2009 Effect of smoking cessation advice on cardiovascular disease. ---
929  2009 Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. ---
930  2009 Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. ---
931  2009 Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. ECMO
932  2009 Estimating preference-based health utilities index mark 3 utility scores for childhood conditions in England and Scotland. CI, CLAD, HUI3, OLS
933  2009 Estimation of mortality savings due to a national program for diabetes care. PYLL
934  2009 Evaluating the claim of enhanced persistence: the case of osteoporosis and implications for payers. BMD, CEA, ICERs
935  2009 Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. ICER
936  2009 Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis. ---
937  2009 Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. BMI
938  2009 Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. CSII, DM, ICER, MDI
939  2009 Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study. ICER, PD, SF-6D
940  2009 Health-related quality of life in 5-year-old very low birth weight infants. HRQoL
941  2009 Health-related quality of life of Southern Chinese with chronic hepatitis B infection. CHB, CLDQ, HCC, HRQoL, SF-36v2
942  2009 Health-related quality of life, quality-adjusted life years, and quality-adjusted life expectancy in new york city from 1995 to 2006. BRFSS, LE, NYC, QALE
943  2009 Hepatocellular adenoma: cost-effectiveness of different treatment strategies. HA, RFA, TAE
944  2009 Incorporating extrinsic goals into decision and cost-effectiveness analyses. AVMs
945  2009 Intervention study shows outpatient cardiac rehabilitation to be economically at least as attractive as inpatient rehabilitation. ---
946  2009 Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis. ICER
947  2009 Is the United States ready for QALYs? ---
948  2009 Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. QALE
949  2009 Long-term outcome and quality-adjusted life years after severe sepsis. CI, EQ-5D, ICU, IQR, QOL, VAS
950  2009 Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. EORTC
951  2009 Maternal and neonatal outcomes of elective induction of labor. ---
952  2009 Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. LGD, UC
953  2009 Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years. INB
954  2009 Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). pADEs
955  2009 Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. CHD, DM, LDL-C, TG
956  2009 Outcomes of maximal androgen blockade in prostate cancer patients at a health area with type 2 reference hospital. Part 2. Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility. MAB
957  2009 Personal and societal health quality lost to tuberculosis. PIAT, PTB
958  2009 Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. CIs
959  2009 Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses. CT, EPID, WTP
960  2009 Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients. ADL, HRQoL
961  2009 Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment. SD
962  2009 Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura. EVPI, EVPPI, ITP, IVIG, WTP
963  2009 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. EORTC, FL, NHL, NICE, STA
964  2009 Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. DVT, ERG, NICE, PE, RCTs, STA, THR, TKR, VTE
965  2009 Screening for postnatal depression in primary care: cost effectiveness analysis. ICER
966  2009 Selective laser photocoagulation versus serial amniodrainage for the treatment of twin-twin transfusion syndrome: a cost-effectiveness analysis. AD, CP, SLP, TTTS
967  2009 Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? AF
968  2009 Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis. GPs
969  2009 The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model. CI, IHS, LVEF, NYHA, QOL
970  2009 The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. ICER, ICU, PSA, RSV
971  2009 The cost-effectiveness of hormone therapy in younger and older postmenopausal women. ---
972  2009 The cost-effectiveness of increasing kidney transplantation and home-based dialysis. ESKD, HD, PD, RRT
973  2009 The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. dB
974  2009 The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. LY, SNB, WEX
975  2009 The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma. MRI, NPC, PET
976  2009 The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. AS, RA
977  2009 The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. EBC, HER2, ICER, MBC
978  2009 The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. DGF, FDA, IGF, MPT, PNF, PPART, RCTs
979  2009 The effectiveness of a training for patients with unexplained physical symptoms: protocol of a cognitive behavioral group training and randomized controlled trial. ---
980  2009 The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins. CAD, LY
981  2009 The health and economic consequences of moderate alcohol consumption in Germany 2002. YPL
982  2009 The health and economic consequences of osteopenia- and osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050. OHF, YPLL
983  2009 The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. DMTs, EDSS, MS, QOL
984  2009 The national burden of musculoskeletal pain in Japan: Projections to the year 2055. ---
985  2009 The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. EGFR, NSCLC
986  2009 The social costs of childhood lead exposure in the post-lead regulation era. ---
987  2009 The statewide burden of obesity, smoking, low income and chronic diseases in the United States. QALE
988  2009 The use of paclitaxel in the management of early stage breast cancer. DFS, ERG, ICER, NICE, OS, STA
989  2009 Use of Global Visual Acuity Data in a time trade-off approach to calculate the cost utility of cataract surgery. TTO, VA
990  2009 Using DCE and ranking data to estimate cardinal values for health states for deriving a preference-based single index from the sexual quality of life questionnaire. DCEs, TTO
991  2009 Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. ---
992  2009 Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis. OST
993  2009 Uterine artery embolization, hysterectomy, or myomectomy for symptomatic uterine fibroids: a cost-utility analysis. UAE
994  2009 Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations. BCVA, BSC, CEAs, HRQoL, nAMD, UK, vPDT
995  2009 When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. MDD, SSRIs
996  2009 [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea]. ADV, CHB, LMV
997  2009 [Economic evaluation and budget impact analysis of the Endeavor drug-eluting stent in Spain]. BMS, CABG, DES, MACE
998  2009 [Use of European Quality of Life-5 Dimensions (EQ-5D) questionnary to value the health related quality of life variation because of influenza]. EQ-5D, HRQoL
999  2010 A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children. ---
1000  2010 A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. HPV, ICER
1001  2010 A cost-utility analysis of microwave endometrial ablation versus thermal balloon endometrial ablation. CI, MEA, TBALL
1002  2010 A cost-utility analysis of nonsurgical management, total wrist arthroplasty, and total wrist arthrodesis in rheumatoid arthritis. ---
1003  2010 A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy. ICER
1004  2010 A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BT-ICT, HSCT, ICER, THB
1005  2010 A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. ---
1006  2010 A health-economic analysis of porcine islet xenotransplantation. ---
1007  2010 A multicentred randomised controlled trial of a primary care-based cognitive behavioural programme for low back pain. The Back Skills Training (BeST) trial. AM, CBA, CI, LBP, MVK, RMQ
1008  2010 A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care. CanDys, WTP
1009  2010 A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. INB
1010  2010 A randomised controlled trial of cognitive behaviour therapy and motivational interviewing for people with Type 1 diabetes mellitus with persistent sub-optimal glycaemic control: a Diabetes and Psychological Therapies (ADaPT) study. ADaPT, CBT, CI, EQ-5D, MET, SF-36
1011  2010 A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. EVPI, HF, ICERs, MI, RCTs, VOI
1012  2010 Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. IMRT, QALE
1013  2010 Acupuncture for irritable bowel syndrome: a protocol for a pragmatic randomised controlled trial. CEACs, IBS, SSS
1014  2010 Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. CWU, NMB
1015  2010 An economic analysis of hand transplantation in the United States. ---
1016  2010 An economic evaluation of treatments for HIV-associated facial lipoatrophy: a cost-utility analysis. FLA, PLWH
1017  2010 An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. CHOP, CVP, FL, MCP, NHS
1018  2010 Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. ---
1019  2010 BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. ADL, ARAT, CI, EQ-5D
1020  2010 Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. aSAH, HRQL, ICD-10, NHS
1021  2010 Caring for the Uninsured with Prostate Cancer: A Comparison of Four Policy Alternatives in California. ICERs
1022  2010 Chronic pain following donor nephrectomy--a study of the incidence, nature and impact of chronic post-nephrectomy pain. ---
1023  2010 Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. BD-IPMN, ICER
1024  2010 Contribution of intangible costs to the economic burden of multiple sclerosis. HRQoL, MS, WTP
1025  2010 Cost effectiveness analysis of hemiarthroplasty and total shoulder arthroplasty. HA, TSA
1026  2010 Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis. AEs, NHS, PHN
1027  2010 Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. CTE, SBFT
1028  2010 Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. PI
1029  2010 Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. AE, SNRI, SSRI
1030  2010 Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study). SAPASI
1031  2010 Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy. BCG, LTBI, QFT, RA, TB, TNF-alpha, TST
1032  2010 Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. BCG, CXR, LTBI, QFT, TB
1033  2010 Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet. GFD, ICER
1034  2010 Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. CKD, GFR, LYG, NHS, SHPT, VDR
1035  2010 Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. WTP
1036  2010 Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. ---
1037  2010 Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. CQG
1038  2010 Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. CVD, ICER
1039  2010 Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. CHD, COPD, ICER, LYs
1040  2010 Cost-effectiveness analysis of a rural telemedicine collaborative care intervention for depression. ---
1041  2010 Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner's care for panic disorder. BAI, GP, ICERs
1042  2010 Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. AI, ATAC, CEA, EBC
1043  2010 Cost-effectiveness analysis of endovascular versus open surgical repair of acute abdominal aortic aneurysms based on worldwide experience. AAA, EVAR
1044  2010 Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. HPV, ICERs, PSAs
1045  2010 Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. BSC, ICER, LYs, mCRC
1046  2010 Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. LYG, NSCLC, PFS
1047  2010 Cost-effectiveness analysis of protected carotid artery stent placement versus endarterectomy in high-risk patients. CAS, CEA, ICERs
1048  2010 Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. HR, ICERs, RS
1049  2010 Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. ---
1050  2010 Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania. LYG
1051  2010 Cost-effectiveness of 21 alternative cervical cancer screening strategies. CCS, HPV DNA, LBC, PAP
1052  2010 Cost-effectiveness of a minimal intervention for stress-related sick leave in general practice: results of an economic evaluation alongside a pragmatic randomised control trial. MISS, UC
1053  2010 Cost-effectiveness of a short stay admission programme for breast cancer surgery. CAU, SSP
1054  2010 Cost-effectiveness of abdominal aortic aneurysm repair based on aneurysm size. AAA, EVAR
1055  2010 Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. ICERs
1056  2010 Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. CKD
1057  2010 Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. ICER, LY
1058  2010 Cost-effectiveness of autologous retinal pigment epithelium and choroid translocation in neovascular AMD. AMD, PATCH, PSA
1059  2010 Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. QOL
1060  2010 Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. ---
1061  2010 Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study. ICER, SUI, SUIT
1062  2010 Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom. EECP, HRQoL
1063  2010 Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. NHS, NSCLC
1064  2010 Cost-effectiveness of guided self-help treatment for recurrent binge eating. CBT-GSH, CEA, TAU
1065  2010 Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients. ACCP, EAST, IVCFs, PE, VTE
1066  2010 Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. HPV
1067  2010 Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. CC, ICC, ICER, QOL
1068  2010 Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors. CHF, ICER
1069  2010 Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. CHF, ICDs, ICER, PHS
1070  2010 Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. ICER, UC
1071  2010 Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. ARAMIS, ART, ICER, OBT
1072  2010 Cost-effectiveness of medical nutrition therapy and therapeutically designed meals for older adults with cardiovascular disease. MNT
1073  2010 Cost-effectiveness of newborn circumcision in reducing lifetime HIV risk among U.S. males. ---
1074  2010 Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. CHB
1075  2010 Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. GAD, HAMA
1076  2010 Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. rt-PA
1077  2010 Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. ACE, ICER
1078  2010 Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. ---
1079  2010 Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. HRQoL, NHS, SGA
1080  2010 Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. hs-CRP, LDL
1081  2010 Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. ---
1082  2010 Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. QALE, US
1083  2010 Cost-effectiveness of tailored print communication, telephone motivational interviewing, and a combination of the two: results of an economic evaluation alongside the Vitalum randomized controlled trial. TMI, TPC
1084  2010 Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. ---
1085  2010 Cost-effectiveness of the Boston keratoprosthesis. Boston Kpro, PK, PMMA
1086  2010 Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. DCP, ICERs
1087  2010 Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. CBT, NHS
1088  2010 Cost-effectiveness of traditional and endovenous treatments for varicose veins. EVLA, GSV, ICER, NHS, RFA, UGFS
1089  2010 Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. HPV, ICERs, LBC
1090  2010 Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG) versus fresh frozen plasma (FFP) in critically Ill patients in the UK. FFP
1091  2010 Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom. LGS
1092  2010 Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia. VWD
1093  2010 Cost-utility and value-of-information analysis of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. DLC, ELC, NHS
1094  2010 Cost-utility of a cardiovascular prevention program in highly educated adults: intermediate results of a randomized controlled trial. ---
1095  2010 Cost-utility of breast reduction surgery--a prospective study. HRQoL
1096  2010 Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. ABAT, ADAL, BSC, CEAF, ETAN, ICERs, INFL, RTX
1097  2010 Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. ALF, HRQoL, ICU, MARS
1098  2010 Cost-utility of treatment of bulimia nervosa. EDI, HRQoL
1099  2010 Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. ---
1100  2010 Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. SEG, TAC
1101  2010 Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. DESMOND
1102  2010 Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. ---
1103  2010 Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder. ECT, MDD
1104  2010 Do the potential benefits of metal-on-metal hip resurfacing justify the increased cost and risk of complications? ICER, MoM HRA, THA
1105  2010 Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. ART, ICERs, OIs
1106  2010 Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. CI, CKD, eGFR, HR, RRT
1107  2010 Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: a decision analysis. STN-DBS
1108  2010 Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. PCT
1109  2010 Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. TIIP, UIIP
1110  2010 Economic assessment of cardiac resynchronization therapy. CRT, ODT
1111  2010 Economic evaluation of a workplace intervention for sick-listed employees with distress. CBA, CEA, CUA, RTW
1112  2010 Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. ACT, DD, G-CSF, ICERs, LYs
1113  2010 Economic evaluation of the treatment of grade II haemorrhoids: a comparison of stapled haemorrhoidopexy and rubber band ligation. RBL, SH
1114  2010 Economic evaluation of toric intraocular lens: a short- and long-term decision analytic model. IOLs, IRC
1115  2010 Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. MDD
1116  2010 Economics of influenza vaccine administration timing for children. ---
1117  2010 Effect of integrated care for sick listed patients with chronic low back pain: economic evaluation alongside a randomised controlled trial. ---
1118  2010 Effect of preventive primary care outreach on health related quality of life among older adults at risk of functional decline: randomised controlled trial. ---
1119  2010 Estimates of the cost-effectiveness of pediatric bilateral cochlear implantation. INB, TTO, VAS
1120  2010 Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. I-QOL, UI
1121  2010 Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. EQ-5D, HAQ, RA, SF-6D
1122  2010 Health and cost consequences of surgical versus conservative treatment for a comminuted proximal humeral fracture in elderly patients. CI
1123  2010 Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. BCS, DCIS, RT
1124  2010 Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. HAQ-DI, RA, TNF
1125  2010 Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? COPD, INTERCOM, SGRQ
1126  2010 Is prophylactic fixation a cost-effective method to prevent a future contralateral fragility hip fracture? ---
1127  2010 Is the EQ-5D fit for purpose in mental health? ---
1128  2010 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. FP, SALM, SFC, TORCH
1129  2010 Justifying terminal care by 'retrospective quality-adjusted life-years'. ---
1130  2010 Long-term health and economic impact of preventing and reducing overweight and obesity in adolescence. ---
1131  2010 Management of patients with acoustic neuromas: a Markov decision analysis. ---
1132  2010 Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. HL, HUI, OLS, OME
1133  2010 MCV vaccination in the presence of vaccine-associated Guillain-Barre Syndrome risk: a decision analysis approach. GBS
1134  2010 Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. CG, CI, DPP-4, GLP-1, NICE, NPH, RevMan, RR, UKPDS
1135  2010 Obesity-related quality-adjusted life years lost in the U.S. from 1993 to 2008. ---
1136  2010 One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure. ARF, ICU, MV, QOL
1137  2010 Optimizing statin treatment for primary prevention of coronary artery disease. CAD, NCEP, treat to target
1138  2010 Pelvic floor consequences of cesarean delivery on maternal request in women with a single birth: a cost-effectiveness analysis. CDMR, CI, PFDs, TOL
1139  2010 Population based screening for chronic kidney disease: cost effectiveness study. ---
1140  2010 Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. MI
1141  2010 Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. MPR
1142  2010 Potential clinical and economic impact of nonadherence with osteoporosis medications. MPR
1143  2010 Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project. ---
1144  2010 Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. HPV, ICERs
1145  2010 Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. EQ-5D, EQ-VAS, QOL, SF-6D
1146  2010 Quality-adjusted life expectancy benefits of laparoscopic bariatric surgery: a United States perspective. BMI, LAGB, LRYGB
1147  2010 Quality-adjusted life-years and helmet use among motorcyclists sustaining head injuries. QALE
1148  2010 Quality-adjusted life-years, comparative effectiveness in cancer care, and measuring outcomes in the underserved. ARRA, CER
1149  2010 Recent trends and geographic patterns of the burden of disease attributable to smoking. ---
1150  2010 Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. NHS, PMO
1151  2010 Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness. SNM
1152  2010 Second-eye cataract surgery in elderly women: a cost-utility analysis conducted alongside a randomized controlled trial. ---
1153  2010 Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. ICERs, OADs, SMBG, T2DM
1154  2010 Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. ICERs, OADs, SMBG
1155  2010 Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer. ICERs, RR
1156  2010 Suspected carotid artery stenosis: cost-effectiveness of CT angiography in work-up of patients with recent TIA or minor ischemic stroke. CAS, CT, MR, TIA, US
1157  2010 The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. BSC, ICER, ORR, QOL, RCTs, SCLC
1158  2010 The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. ART
1159  2010 The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model. ICER, MDD
1160  2010 The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK. NHS
1161  2010 The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. ER, IR, OAB
1162  2010 The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease. CI, SPHERE
1163  2010 The health and economic effects of HPV DNA screening in The Netherlands. HPV, ICER
1164  2010 The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS). ICH, NEMESIS, QOL, SA
1165  2010 The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. HPV, HTA
1166  2010 The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies. ---
1167  2010 The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis. REAL
1168  2010 The independent contribution of executive functions to health related quality of life in older women. MMSE
1169  2010 The pharmaceutical economics of child psychiatric drug treatment. ADHD, CEAs
1170  2010 Theoretical foundation of patient v. population preferences in calculating QALYs. ---
1171  2010 Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. HCCs, HCV
1172  2010 Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. ERG, HRQoL, ICER, NICE, STA
1173  2010 Trastuzumab beyond progression: a cost-utility analysis. MBC
1174  2010 Treatment of advanced Parkinson's disease in the United States: a cost-utility model. CI, LCE, PD
1175  2010 Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. MPEs
1176  2010 Trends in quality-adjusted life-years lost contributed by smoking and obesity. HRQoL
1177  2010 US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. HAART, IAS-USA, ICER, PI, RAMs
1178  2010 Use of outcomes to evaluate surveillance systems for bioterrorist attacks. AUC, ROC
1179  2010 Value of biologic therapy: a forecasting model in three disease areas. ROI
1180  2010 Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. BP, CVD, DM, LDL-C
1181  2010 Within-trial economic evaluation of diabetes-specific cognitive behaviour therapy in patients with type 2 diabetes and subthreshold depression. ICER
1182  2010 [Cost-effectiveness model of a community-based service for dementia caregivers]. MCS
1183  2011 A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. CHD, HT
1184  2011 A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. HNPCC
1185  2011 A decision analysis of amputation versus reconstruction for severe open tibial fracture from the physician and patient perspectives. ---
1186  2011 A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. AS, BASDAI, BASFI
1187  2011 A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). ICER, SCID
1188  2011 A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. ---
1189  2011 A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. ICUR, NSCLC
1190  2011 An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. BTcP, FBT, INFS, OTFC, PI, UI
1191  2011 Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). ITP, ITP
1192  2011 Arthritis, occupational class, and the aging US workforce. ---
1193  2011 Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. AD, ADL, BSC, MMSE, NHS
1194  2011 Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? CV, HR, PAD
1195  2011 Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence. NICE
1196  2011 Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. CV, INB, NB
1197  2011 Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. LC
1198  2011 Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. CI, HR, ICERs, MI, MRD, NICE, RCTs, TIA
1199  2011 Cohort decomposition for Markov cost-effectiveness models. ---
1200  2011 Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. CHD, CI, CT
1201  2011 Comparison of one and two-stage revision of total hip arthroplasty complicated by infection: a Markov expected-utility decision analysis. ---
1202  2011 Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. UIs
1203  2011 Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. RMDQ
1204  2011 Consumer responses to integrated risk-benefit information associated with the consumption of food. ---
1205  2011 Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected patients in the United States. CHD, ICER, OIs
1206  2011 Cost effectiveness of disc prosthesis versus lumbar fusion in patients with chronic low back pain: randomized controlled trial with 2-year follow-up. FUS, ICER, PLF, PLIF, TDR
1207  2011 Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. ICERs, SCMs, US
1208  2011 Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. ICER
1209  2011 Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. NICE, NRT
1210  2011 Cost effectiveness of screening immigrants for hepatitis B. CHB, HBV, ICER
1211  2011 Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. HRPC, SREs, ZOL
1212  2011 Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. REDUCE
1213  2011 Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System. AIs, ATAC, BIG, IPCW
1214  2011 Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer. ICER, WHI-DM
1215  2011 Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. EFV, HAART, HIV, ICER, STR
1216  2011 Cost-effectiveness analysis of renal replacement therapy in Austria. RRT
1217  2011 Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. ---
1218  2011 Cost-effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study. ICER, ICER, ONS, SF
1219  2011 Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. CAIDE
1220  2011 Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. ILI, TVP, UMV
1221  2011 Cost-effectiveness of ablation surgery in patients with atrial fibrillation undergoing cardiac surgery. AF, AS, UI
1222  2011 Cost-effectiveness of acupuncture care as an adjunct to exercise-based physical therapy for osteoarthritis of the knee. AE, NHS
1223  2011 Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naive human immunodeficiency virus-1 patients in Sweden. CI, HIV-1
1224  2011 Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up. BKP, CI, QOL, VCF
1225  2011 Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). CRT, HF, NYHA, QALY
1226  2011 Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. CGM, DCCT, SMBG, UKPDS, WTP
1227  2011 Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. CBC, CPM, ICER, QOL
1228  2011 Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. AF
1229  2011 Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. AF, ICER
1230  2011 Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. ---
1231  2011 Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. CHF
1232  2011 Cost-effectiveness of homograft heart valve replacement surgery: an introductory study. ICER
1233  2011 Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. ICERs, LYG, T2DM
1234  2011 Cost-effectiveness of intensive inpatient treatments for severely obese children and adolescents in the Netherlands; a randomized controlled trial (HELIOS). NTR
1235  2011 Cost-effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of employees. CXR, QFT, TB
1236  2011 Cost-effectiveness of Internet-based self-management compared with usual care in asthma. ---
1237  2011 Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. CB, CKD, LC, SP
1238  2011 Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. CVD, ESRD, ICERs, ITT, LC, LYS, PSA, SH
1239  2011 Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. BMI, CDM, ICERs, LE, LEAD-1, T2DM, TZD
1240  2011 Cost-effectiveness of lower extremity compression ultrasound in emergency department patients with a high risk of hemodynamically stable pulmonary embolism. CTAs, DVTs, ED, PE, US
1241  2011 Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. MRI, PET, SLNB
1242  2011 Cost-effectiveness of multilevel hemilaminectomy for lumbar stenosis-associated radiculopathy. EQ-5D, ODI, SF-12, VAS-LP
1243  2011 Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States. ---
1244  2011 Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. ---
1245  2011 Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel Assay of cardiac markers (RATPAC) trial. ED, MI, POC, RATPAC, SD
1246  2011 Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. BoNT-A, ICERs, OMT, SNM
1247  2011 Cost-effectiveness of telemetry for hospitalized patients with low-risk chest pain. ACS, ED, mCER, WTP
1248  2011 Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. ---
1249  2011 Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. tPA
1250  2011 Cost-effectiveness of transforaminal lumbar interbody fusion for Grade I degenerative spondylolisthesis. TLIF, VAS
1251  2011 Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom. NSCLC, SREs, ZOL
1252  2011 Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. RCC, SREs, UK, ZOL
1253  2011 Cost-utility analysis of a one-time supervisor telephone contact at 6-weeks post-partum to prevent extended sick leave following maternity leave in The Netherlands: results of an economic evaluation alongside a randomized controlled trial. CP, STC
1254  2011 Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. COPD, CUA
1255  2011 Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. ITI, rFVIIa
1256  2011 Cost-utility of aspirin and proton pump inhibitors for primary prevention. CHD, GI, PPIs
1257  2011 Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. ---
1258  2011 Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. ---
1259  2011 Deriving distributional weights for QALYs through discrete choice experiments. ---
1260  2011 Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation. CCHR, CINAHL, CT, GCS, HDR, ICI, MHI, MVA, PLR, PTS, QUADAS
1261  2011 Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness. WTP
1262  2011 Economic considerations of macular edema therapies. BRVO, CRVO, DME, VA, VEGF
1263  2011 Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. ---
1264  2011 Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. L-AmB
1265  2011 Economic evaluation of dose-response resistance training in older women: a cost-effectiveness and cost-utility analysis. ---
1266  2011 Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. ICER, LYG, mRCC
1267  2011 Economic evaluation of four follow-up strategies after curative treatment for breast cancer: results of an RCT. EGP, ICERs
1268  2011 Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. HCTZ, MI, QOL
1269  2011 Economic evaluation of multidisciplinary rehabilitation after primary total knee arthroplasty based on a randomized controlled trial. TKA
1270  2011 Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. IFN-alpha, LYs, mRCC, PFLYs
1271  2011 Economic evaluation of reamed versus unreamed intramedullary nailing in patients with closed and open tibial fractures: results from the study to prospectively evaluate reamed intramedullary nails in patients with tibial fractures (SPRINT). CI
1272  2011 Economic evaluation of Vacuum Assisted Closure Therapy for the treatment of diabetic foot ulcers in France. AWC, DFUs, VAC
1273  2011 Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. DRG, HF, IRR, LOS, RCTs, RPM
1274  2011 Effect of health-related quality-of-life instrument and quality-adjusted life year calculation method on the number of life years gained in the critical care setting. HRQoL
1275  2011 Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. ART, IDU, IDUs
1276  2011 Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. GLP-1, kr
1277  2011 Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. NPH
1278  2011 Falls-related self-efficacy is independently associated with quality-adjusted life years in older women. HRQL
1279  2011 Golimumab for the treatment of psoriatic arthritis. ACR, CI, ERG, HAQ, ICERs, MTC, PASI, PsA, PsARC, RCT, RR, TNF
1280  2011 Government use licenses in Thailand: an assessment of the health and economic impacts. FDI, GSP, MOPH
1281  2011 Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction. PCI
1282  2011 Health utility and survival after hospital admission with acute cardiogenic pulmonary oedema. ACPO, CPAP, NIPPV, NIV
1283  2011 Health-related quality of life after a drowning incident as a child. CPR, HRQoL
1284  2011 Herpes zoster in Germany: quantifying the burden of disease. ASHIP, FHM, HZ, PHN, VZV
1285  2011 HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. AHI, IDUs, MSM, NAAT
1286  2011 Hysterectomy, endometrial ablation and Mirena for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. CI, EA, IPD, IQR, OR, WMD
1287  2011 Improving the quality of pressure ulcer care with prevention: a cost-effectiveness analysis. HAPUs
1288  2011 Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients. GLM's
1289  2011 Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. CVD
1290  2011 Intussusception in children: cost-effectiveness of ultrasound vs diagnostic contrast enema. CE, US/CE
1291  2011 Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. DFO, DFP, DFX, ICERs
1292  2011 Is behavioral graded activity cost-effective in comparison with manual therapy for patients with subacute neck pain? An economic evaluation alongside a randomized clinical trial. BGA, CEA, MT
1293  2011 Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? SRM
1294  2011 Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. CI, ICU, LYs
1295  2011 Lifestyle behaviours and quality-adjusted life years in middle and older age. EPIC
1296  2011 Liraglutide for the treatment of type 2 diabetes. BMI, ERG, LEAD-5, NICE, SBP
1297  2011 Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone. ---
1298  2011 Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. SEK
1299  2011 Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon. DET, eSET, IVF
1300  2011 Pharmacoeconomic evaluation of warfarin pharmacogenomics. ---
1301  2011 Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. 4-NS, CI, CT, FN, FP, MRI, PET, QUADAS, SLNB, USPIO
1302  2011 Possible net harms of breast cancer screening: updated modelling of Forrest report. ---
1303  2011 Predicting EQ-5D values using the SGRQ. GLMs, HTA, OLS, RMSE, SGRQ
1304  2011 Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample. NHMS
1305  2011 Preventing pressure ulcers in long-term care: a cost-effectiveness analysis. ---
1306  2011 Quality of life and cost-utility assessment after strabismus surgery in adults. VFQ-25
1307  2011 Risk management in HIV/AIDS: ethical and economic issues associated with restricting HAART access only to adherent patients. HAART, HIVDR, ICER
1308  2011 Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. MRSA
1309  2011 Should TIA patients be hospitalized or referred to a same-day clinic?: a decision analysis. ICER, tPA
1310  2011 Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes. FIELD
1311  2011 Simultaneous liver kidney transplantation: a medical decision analysis. ESLD, ESRD, LTA
1312  2011 Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore. ---
1313  2011 Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain. DTP
1314  2011 Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. ---
1315  2011 Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. AZA, CD, ICER, IFX
1316  2011 The burden of mental disorders in primary care. ---
1317  2011 The chronic kidney disease model: a general purpose model of disease progression and treatment. CKD
1318  2011 The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. HRQoL, JPY
1319  2011 The cost of changing physical activity behaviour: evidence from a "physical activity pathway" in the primary care setting. NHS
1320  2011 The cost-effectiveness of a modestly effective HIV vaccine in the United States. ---
1321  2011 The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. CMF, E-CMF, NHS, RCTs
1322  2011 The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach. ---
1323  2011 The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. HBV, HCV, HIV, ID-NAT, SEK
1324  2011 The cost-effectiveness of screening for chronic hepatitis B infection in the United States. HBV
1325  2011 The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. ILI, MSM
1326  2011 The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. ICERs
1327  2011 The cost-effectiveness of venous-converted acid-base and blood gas status in pulmonary medical departments. ICER, WTP
1328  2011 The cost-utility of bilateral cochlear implantation: a systematic review. ---
1329  2011 The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury. ALI, CVC, FACTT, PAC, QOL
1330  2011 The effect of the expenditure increase in the morbidity and the mortality of patients with end stage renal disease: the USA case. ESRD, HD, PD
1331  2011 The impact of adding an extra dimension to a preference-based measure. CSPBMs
1332  2011 The impact of anogenital warts on health-related quality of life: a 6-month prospective study. HPV
1333  2011 The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America. DALYs, PAHO, PCVs
1334  2011 The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. ---
1335  2011 The pursuit of transparency and quality improvement in cost-effectiveness analysis - a case study in disease-modifying drugs for the treatment of multiple sclerosis. CBA, CEA, CEA, CUA
1336  2011 The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. AMI, CHD, CI, ED, OR
1337  2011 The societal burden of poor persistence to treatment of osteoporosis in Sweden. ---
1338  2011 The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature. ---
1339  2011 The value of atorvastatin over the product life cycle in the United States. ICER
1340  2011 Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. ACS, ICER
1341  2011 Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. BSC, ICER, RCTs, SCLC
1342  2011 Trans-obturator tape compared with tension-free vaginal tape in the surgical treatment of stress urinary incontinence: a cost utility analysis. RCT, SUI, TOT, TVT
1343  2011 Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. 5-FU, CF, ECF, EOX, ERG, FISH, HCF, HER2, ICER, IHC, RCT
1344  2011 Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. ---
1345  2011 Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. CMV
1346  2011 Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia. DA, GDP, mCRC, WHO
1347  2011 VLED and formula LED in the management of type 2 diabetes: defining the clinical need and research requirements. LELD, VLED
1348  2011 Welfare, QALYs, and costs - a comment. ---
1349  2011 What treatment for early-stage glottic carcinoma among adult patients: CO2 endolaryngeal laser excision versus standard fractionated external beam radiation is superior in terms of cost utility? CI, LC, LFS, OR, OS
1350  2011 Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HCC, HR, LRT, MELD, POLT, QOL, SOLT
1351  2011 [Cost utility of renal transplant vs. hemodialysis in the treatment of end stage chronic kidney failure in a Peruvian hospital]. CDRT, CU, HD, ICU
1352  2011 [Cost-effectiveness analysis of pneumococcal vaccination in Spain]. AOM, MDS
1353  2011 [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus]. IG, T2DM
1354  2011 [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain]. BPH, ICER, TAM
1355  2011 [Cost-utility of the vaccine against the Human Papiloma Virus in Peruvian women]. HPV, ICUR, UCC
1356  2011 [Health-economic evaluation of magnetic resonance imaging before biopsy for diagnosis of prostate cancer]. PCa
1357  2012 A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol. OT, TIA, UK
1358  2012 A cost-effectiveness analysis of early vs late reconstruction of iatrogenic bile duct injuries. BDI, EHBS, LHBS, PSR
1359  2012 A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. LAAI
1360  2012 A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. ACS, CR, PCI
1361  2012 A systematic review of cost-effectiveness analyses alongside randomised controlled trials of acupuncture. CBA, CEA, CUA, ICERs, RCTs
1362  2012 A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen for the treatment of bee and wasp venom allergy. AAI, AG, ARs, HDA, ICER, IgE, QOL, RCTs, VIT
1363  2012 A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin. ---
1364  2012 A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years. SG, TTO, WTP
1365  2012 Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: a cost-effectiveness analysis. APT, CBT, GET, ICERs, SMC
1366  2012 Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. EORTC, PF
1367  2012 An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity. e-LEEM, EVPI, QALY
1368  2012 An economic model of school-based behavioral interventions to prevent sexually transmitted infections. HRQoL, STI
1369  2012 Application of classic utilities to published pediatric cost-utility studies. CEA, CUAs, SAs
1370  2012 Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. ACCORD, CVD, FT, HRQoL, HU, ICCs, SF-6D, SF-6D
1371  2012 Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. ICH, ITP, IVIG
1372  2012 Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. CD, CZP, ICER, NAT, TNF, WTP
1373  2012 Changes to the statin prescribing policy in Belgium: potential impact in clinical and economic terms. CVD
1374  2012 Clinical applications of cost analysis of diabetic macular edema treatments. DME, IVTA, VA, VEGF
1375  2012 Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. ICER, LYs
1376  2012 Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. CMT, CNS
1377  2012 Community falls prevention for people who call an emergency ambulance after a fall: an economic evaluation alongside a randomised controlled trial. ---
1378  2012 Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. 6-MP, ADRs, AZA, CD, ICER, RCTs
1379  2012 Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: Recognizing who can benefit. DBD, DCD, HCC, ICER, MELD
1380  2012 Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. ---
1381  2012 Comparison of FACT- and EQ-5D-based utility scores in cancer. FACT
1382  2012 Comparison of lifetime incremental cost:utility ratios of surgery relative to failed medical management for the treatment of hip, knee and spine osteoarthritis modelled using 2-year postsurgical values. ICURs, OA, SF, THA, TKA
1383  2012 Cost effectiveness analysis of graft options in spinal fusion surgery using a Markov model. CCA, DBM, ICBG, RhBMP
1384  2012 Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. ---
1385  2012 Cost effectiveness of abdominal aortic aneurysm screening and rescreening in men in a modern context: evaluation of a hypothetical cohort using a decision analytical model. ---
1386  2012 Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. AIs, BMD, EBC, HR, ICER
1387  2012 Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. GEP
1388  2012 Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. HAQ, ICERs, PASI, PSA, PsARC
1389  2012 Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. ADHD, ATX, CEA, GXR, MAIC
1390  2012 Cost effectiveness of infant vaccination for rotavirus in Canada. IMPACT
1391  2012 Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening. BCG, CXR, QFT, TB, TST
1392  2012 Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations. RT
1393  2012 Cost effectiveness of prostacyclins in pulmonary arterial hypertension. EPO, ICER, ILO, LYG, NHS, NYHA, PAH, TRE
1394  2012 Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. ICER, T2DM, UKPDS
1395  2012 Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. ICERs, IDUs, ORT
1396  2012 Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. NHAS
1397  2012 Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. ---
1398  2012 Cost of acute coronary syndrome in Switzerland in 2008. ACS
1399  2012 Cost per quality-adjusted life year gained of laminectomy and extension of instrumented fusion for adjacent-segment disease: defining the value of surgical intervention. ASD
1400  2012 Cost per quality-adjusted life year gained of revision neural decompression and instrumented fusion for same-level recurrent lumbar stenosis: defining the value of surgical intervention. ---
1401  2012 Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. UC
1402  2012 Cost-effectiveness analysis of a community health worker intervention for low-income Hispanic adults with diabetes. CHWs
1403  2012 Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. ICER, LYS, SRS
1404  2012 Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. ER, ICE, NICE
1405  2012 Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. ICER
1406  2012 Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. HAART, HIV, ICER, STR
1407  2012 Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. CDMS, EDSS, IFNB-1b, MS
1408  2012 Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. IR
1409  2012 Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. CP, GDP, ICER, MMS, PEI, PERT
1410  2012 Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. AMD, UI
1411  2012 Cost-effectiveness analysis of repeat fine-needle aspiration for thyroid biopsies read as atypia of undetermined significance. AUS, FLUS, FNA, NCI
1412  2012 Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. CV, CVD, SCORE
1413  2012 Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands. ABS, DGP, SNM
1414  2012 Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. IMRT, SBRT
1415  2012 Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. IMRT, SBRT
1416  2012 Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. LYs
1417  2012 Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. FP/S, MM, NHS
1418  2012 Cost-effectiveness at two years in the VA Open Versus Endovascular Repair Trial. AAA
1419  2012 Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity. ICERs
1420  2012 Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. CLI, ICERs
1421  2012 Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). ACT, ICER
1422  2012 Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States. HIV
1423  2012 Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. CHD, LDL-C, SBP, UC
1424  2012 Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. CLL, OS, PFS, R-FC
1425  2012 Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. ICER
1426  2012 Cost-effectiveness of an electronic medical record based clinical decision support system. CDS, EMRs
1427  2012 Cost-effectiveness of an exercise program during pregnancy to prevent gestational diabetes: results of an economic evaluation alongside a randomised controlled trial. GDM, RCT
1428  2012 Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. AF
1429  2012 Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. AF
1430  2012 Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. AF
1431  2012 Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. H-GPI, PPCI, STEMI
1432  2012 Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension. ---
1433  2012 Cost-effectiveness of carotid artery stent placement versus endarterectomy in patients with carotid artery stenosis. CAS, CEA, CREST, ICERs, MI
1434  2012 Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. HPV, MISCAN
1435  2012 Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. ICERs, PTH, SHPT
1436  2012 Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ACTIVE-A, AF
1437  2012 Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. AF, ICERs
1438  2012 Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. ICER, SREs
1439  2012 Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CI
1440  2012 Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department. CT, CT/LP, CT/MRA, ED, SAH
1441  2012 Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting. ---
1442  2012 Cost-effectiveness of exercise programs in type 2 diabetes. DARE
1443  2012 Cost-effectiveness of expanded newborn screening in Texas. ---
1444  2012 Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. ICERs, IFN, RRMS
1445  2012 Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. BTC, ICER, PSA
1446  2012 Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. HCV, ICER, IDUs
1447  2012 Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. CD, CTE, ICERs, LY, MRE, QALY
1448  2012 Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. CC, CI, LC, SH
1449  2012 Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. CE
1450  2012 Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. MMT, WHOQOL-BREF
1451  2012 Cost-effectiveness of minimally invasive versus open transforaminal lumbar interbody fusion for degenerative spondylolisthesis associated low-back and leg pain over two years. ICER, MIS-TLIF
1452  2012 Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature. ---
1453  2012 Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. ---
1454  2012 Cost-effectiveness of nutritional intervention on healing of pressure ulcers. PUDs
1455  2012 Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. SNAE
1456  2012 Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. DME, ICER
1457  2012 Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. AF, ICERs
1458  2012 Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. CVD, LYG
1459  2012 Cost-effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. SU
1460  2012 Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. CORE, MDI, SAPT
1461  2012 Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. ICER, ODT, SOT
1462  2012 Cost-effectiveness of substituting dual-energy CT for SPECT in the assessment of myocardial perfusion for the workup of coronary artery disease. CAD, DECT, ICER, SPECT
1463  2012 Cost-effectiveness of supplementing a broth-enriched culture test with the Xpert meticillin-resistant Staphylococcus aureus (MRSA) assay for screening inpatients at high risk of MRSA. MRSA
1464  2012 Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. PR
1465  2012 Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). AVR, PARTNER, PARTNER A, TA, TAVR, TF
1466  2012 Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. ICER, SAVR, TAVI
1467  2012 Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. ---
1468  2012 Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. CLO, ICER, MM, MMIX, OS, PFS, SREs, ZOL
1469  2012 Cost-utility analysis of adjuvant therapies for breast cancer in Iran. EORTC, FAC
1470  2012 Cost-utility analysis of different treatments for post-traumatic stress disorder in sexually abused children. ICERs, PTSD, SSRI
1471  2012 Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. T2DM
1472  2012 Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. CU
1473  2012 Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. GEJ, HER2, ICERs
1474  2012 Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. CM, ICER
1475  2012 Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. AF, CI, ICH, ITC, RR
1476  2012 Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. DBS, MMT, QOL
1477  2012 Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. EVPI, EVPPI, NMB, NYHA
1478  2012 Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. FRC, FXD, HIV/AIDS, ICURs, MEPS
1479  2012 Early hospital discharge of infants born to group B streptococci-positive mothers: a decision analysis. GBS, IAP, ICER
1480  2012 Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. CC, CHB, DC, HBeAg, HCC
1481  2012 Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naive and -experienced United Kingdom patients in 2011. ART, CHD, HIV, HRQoL, ICER, UK, VL
1482  2012 Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ICER, LY, MI, NSTEMI, UA
1483  2012 Economic evaluation of different treatment modalities in acute kidney injury. AKI, CONS, CRRT, IRRT
1484  2012 Economic evaluation of plerixafor for stem cell mobilization. ASCT, DLBCL, G-CSF, ICUR, NHL, SCM
1485  2012 Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. BCS, ICERs
1486  2012 Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma. BSC, EVPI, FL, R-CHOP, RCHOP
1487  2012 Economic evaluation of strategies to reduce sudden cardiac death in young athletes. ECG, SCD
1488  2012 Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population. BS, GDP, ICER, LYG, RDS
1489  2012 Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. OPTION, RA, tDMARDs, TNF
1490  2012 Economic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts. ---
1491  2012 Economics of mycotoxins: evaluating costs to society and cost-effectiveness of interventions. DALYs
1492  2012 Effect of discounting on estimation of benefits determined by hepatitis C treatment. SVR
1493  2012 Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. ALND, FN, SLNB
1494  2012 Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation. CGA, FH, ICERs, LDL-C
1495  2012 EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. CR
1496  2012 Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery. EMU, OHTAC, VEEG
1497  2012 Establishing the cost-effectiveness of percutaneous coronary intervention for chronic total occlusion in stable angina: a decision-analytic model. CTO, OMT, PCI
1498  2012 Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. CHD, ESRD, QALE, RLE
1499  2012 Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. IPSS, LUTS, OAB, PBO, TOL
1500  2012 Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model. AWD, NHS, ORS, PSA
1501  2012 Evaluating the cost-effectiveness of prenatal surgery for myelomeningocele: a decision analysis. ---
1502  2012 Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis. ---
1503  2012 Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. ICERs, SVT
1504  2012 Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. COPD
1505  2012 Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. AD, aMCI, APOE, EVPI, ICER
1506  2012 Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. AO, CE, LYs, SG
1507  2012 Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. BP, PIO
1508  2012 Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. GLA, NPH, SHI
1509  2012 Health-related quality of life among children with acute lymphoblastic leukemia. ALL, HRQL, HUI
1510  2012 Hemiarthroplasty compared to internal fixation with percutaneous cannulated screws as treatment of displaced femoral neck fractures in the elderly: cost-utility analysis performed alongside a randomized, controlled trial. CUA
1511  2012 Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. ESAs, ESRD, ICER
1512  2012 Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations. CRC
1513  2012 Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. DXA, ICERs
1514  2012 Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: a Markov model simulation. IFG, T2DM
1515  2012 Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained. ILRs, NHS, NICE, TLOC
1516  2012 Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis. GDP, ICER, NFZ, NIP
1517  2012 Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. AFDs, CALM, CBT, CI, ER, GAD, INB, PD, PTSD, SAD, UC
1518  2012 Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. IHC/BRAF, QOL
1519  2012 Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. IHC/BRAF, QOL
1520  2012 Informing shared decisions about advance directives for patients with severe chronic obstructive pulmonary disease: a modeling approach. DNI, ETT
1521  2012 Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. HPV
1522  2012 Is aggressive treatment of traumatic brain injury cost-effective? GOS, TBI
1523  2012 Is subtotal thyroidectomy a cost-effective treatment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment options. ATDs, GD, RAI
1524  2012 Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. CAP, LAP/CAP, LYs, PFYs, TRAST/CAP
1525  2012 Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. ---
1526  2012 Long term treatment of atrial fibrillation in elderly patients: a decision analysis. AF, RateC, RhythmC
1527  2012 Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. 21Y-LTF, IFN-beta, MS
1528  2012 Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. BMI, CDM
1529  2012 Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. BMI, ICER, IG, T2DM
1530  2012 Measurement characteristics of the pediatric asthma health outcome measure. ACQ, ACQ5, PAHOM, ROC
1531  2012 Methods and issues associated with the use of quality-adjusted life-years. ---
1532  2012 New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. IL
1533  2012 Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. ALD, NILT
1534  2012 Optimization of PSA screening policies: a comparison of the patient and societal perspectives. ---
1535  2012 Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women. AI, HK
1536  2012 Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence. MDP
1537  2012 Oral nutritional support in malnourished elderly decreases functional limitations with no extra costs. ---
1538  2012 Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. PP-LAI, RIS-LAI
1539  2012 Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. CEAC, COPD, FEV1, ICER, LYs, RC, WTP
1540  2012 Pharmacoeconomics. NHS
1541  2012 Preference-based comparative effectiveness and cost–effectiveness: a review and relevance of value-based medicine for vitreoretinal interventions. CI, PPV
1542  2012 Preoperative breast MRI in early-stage breast cancer. MRI
1543  2012 Public preferences for responsibility versus public preferences for reducing inequalities. ---
1544  2012 Quality of life measures for food allergy. DBPCFC, HRQL, MCID, NNT
1545  2012 Quality-adjusted life-years for the estimation of effectiveness of screening programs: a systematic literature review. HRQoL
1546  2012 Quality-of-life effects of prostate-specific antigen screening. ERSPC, MISCAN, PSA
1547  2012 Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population. LE, LYs, RRT
1548  2012 Quantitative benefit-risk assessment using only qualitative information on utilities. ---
1549  2012 Racial disparities in quality-adjusted life-years associated with diabetes and visual impairment. EQ-5D
1550  2012 Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. ASC, LYs, MPM, NICE, RCT
1551  2012 Ranking the disease burden of 14 pathogens in food sources in the United States using attribution data from outbreak investigations and expert elicitation. ---
1552  2012 Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. OKS, TKR
1553  2012 Real-life costs and effects of an implementation program to increase thrombolysis in stroke. CI
1554  2012 Resuscitation of likely nonviable infants: a cost-utility analysis after the Born-Alive Infant Protection Act. ---
1555  2012 Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. ICERs
1556  2012 Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. FSU, MDR-TB, MMR, TB
1557  2012 Screening for gestational diabetes mellitus: are the criteria proposed by the international association of the Diabetes and Pregnancy Study Groups cost-effective? GDM, IADPSG, ICER
1558  2012 SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions. EQ-5D, ICERs, QALY, SF-6D
1559  2012 Simulation optimization of PSA-threshold based prostate cancer screening policies. ---
1560  2012 Smoke alarm giveaway and installation programs: an economic evaluation. ACER, CBA, CEA
1561  2012 Societal value of stem cell therapy in stroke--a modeling study. mRS, SCT
1562  2012 Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. ---
1563  2012 Subgroup economic analysis for glioblastoma in a health resource-limited setting. ICER, NT, RT, TMZ
1564  2012 Support and assessment for fall emergency referrals (SAFER 2) research protocol: cluster randomised trial of the clinical and cost effectiveness of new protocols for emergency ambulance paramedics to assess and refer to appropriate community-based care. NHS
1565  2012 Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. ICER, IOP, NICE
1566  2012 Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial. ICEs, MDD
1567  2012 Synthetic vascular hemodialysis access versus native arteriovenous fistula: a cost-utility analysis. ---
1568  2012 The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. DPP
1569  2012 The cost effectiveness of Nucleic Acid Amplification Techniques for the diagnosis of tuberculosis. ---
1570  2012 The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. CIN, HPV, LYS
1571  2012 The cost utility of reduction mammaplasty at medium-term follow-up: a prospective study. RM
1572  2012 The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. HCV, ICER
1573  2012 The cost-effectiveness of falls prevention interventions for older community-dwelling Australians. ICERs
1574  2012 The cost-effectiveness of paliperidone extended release in Spain. ER
1575  2012 The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. MSM, PrEP
1576  2012 The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. ICER, MET, SU
1577  2012 The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. CHB
1578  2012 The cost-effectiveness of Welcome to Medicare visual acuity screening and a possible alternative welcome to medicare eye evaluation among persons without diagnosed diabetes mellitus. CrI
1579  2012 The economic benefit of hip replacement: a 5-year follow-up of costs and outcomes in the Exeter Primary Outcomes Study. ---
1580  2012 The economic impact of stroke in The Netherlands: the €-Restore4Stroke study. ---
1581  2012 The economics of health care quality and medical errors. IOM
1582  2012 The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands. OD, UC
1583  2012 The Effect of Budgetary Restrictions on Breast Cancer Diagnostic Decisions. MDP
1584  2012 The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. ERT, LSD, MPS I, MPS II, NPC, QOL, SRT
1585  2012 The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease. HRQL, PD
1586  2012 The local burden of emotional disorders. An analysis based on a large health survey in Catalonia (Spain). HRQoL
1587  2012 The psychosocial impact of an abnormal cervical smear result. HRQoL, STAI
1588  2012 Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B). SAVR, TAVI
1589  2012 Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. ---
1590  2012 Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. ---
1591  2012 Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. ---
1592  2012 Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? CrI, EVPI, ICER
1593  2012 What is the optimal threshold at which to recommend breast biopsy? LRM, MDP
1594  2012 Which long-acting bronchodilator is most cost-effective for the treatment of COPD? ICER, UI
1595  2012 [An adapted model of cost-effectiveness analysis for the drug entecavir vs pegylated interferon in Venezuela]. ---
1596  2012 [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan]. ICER
1597  2012 [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line]. FL, LYG
1598  2012 [Cost-effectiveness evaluation of seven screening strategies for nasopharyngeal carcinoma]. ICER, NPC
1599  2012 [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China]. ---
1600  2012 [Health economics evaluation of magnetic resonance imaging for the staging of prostate cancer for Austria and Germany]. PCa
1601  2013 A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. ICERs, RE-LY
1602  2013 A Cost-Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China. ARBs, HTN, MI
1603  2013 A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. ---
1604  2013 A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. CIS, MS, PFLYs, QOL, SEK, TIW
1605  2013 A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. LDCT
1606  2013 A decision-analytic Markov model to compare the cost-utility of anterior repair augmented with synthetic mesh compared with non-mesh repair in women with surgically treated prolapse. ICER
1607  2013 A lesson in business: cost-effectiveness analysis of a novel financial incentive intervention for increasing physical activity in the workplace. CEA, CEACs, EVPI, ICERs, PAL, QOL, WTP
1608  2013 A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia. CI, HbA1c
1609  2013 A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. CKD, DCOR, LY, NHS
1610  2013 A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. CHC, MSP, SVR
1611  2013 A new axiomatic approach to the evaluation of population health. HYEs
1612  2013 A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ---
1613  2013 A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. CLP, FACETS, MD, MS, SES
1614  2013 A pragmatic randomised controlled trial of 'PhysioDirect' telephone assessment and advice services for patients with musculoskeletal problems: economic evaluation. NHS
1615  2013 A structured training programme for caregivers of inpatients after stroke (TRACS): a cluster randomised controlled trial and cost-effectiveness analysis. CBS, NEADL, TRACS
1616  2013 A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. CG, EGFR TKI, ICER, NSCLC, PFS
1617  2013 A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention. EOC, IABP, PCI, pVAD
1618  2013 Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. BOCF, EQ-5D, IFX, LOCF, MTX, RA, SD 0.27
1619  2013 Adjunctive colposcopy technologies for examination of the uterine cervix--DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation. AMED, CCT, CDSR, CENTRAL, CIN, CINAHL, DARE, DySIS, HMIC, HPV, HTA, ICER, NHS EED, SCI, SCIE
1620  2013 AESOPS: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of opportunistic screening and stepped care interventions for older hazardous alcohol users in primary care. ADD, CI, DPI, ICER, SD, SF-12
1621  2013 Age-dependent cost-utility of pediatric cochlear implantation. CI, SNHL
1622  2013 An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. IGT
1623  2013 An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. BMD, CAROC, CE, CU
1624  2013 Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. ADONE
1625  2013 Applying the payoff time framework to carotid artery disease management. ---
1626  2013 Are lifestyle interventions in primary care cost-effective?--An analysis based on a Markov model, differences-in-differences approach and the Swedish Bjorknas study. CI, MeSy
1627  2013 Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. ICERs, PWID
1628  2013 Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis. CUA
1629  2013 At what price? A cost-effectiveness analysis comparing trial of labour after previous caesarean versus elective repeat caesarean delivery. CEA, ERCD, TOLAC
1630  2013 Automatic assessment of socioeconomic impact on cardiac rehabilitation. DALYs
1631  2013 Bariatric surgery for the treatment of severely obese patients in South Korea--is it cost effective? ICER
1632  2013 Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BOC, BOC/RGT, HCV, ICERs, NS3
1633  2013 Can donors with high donor risk indices be used cost-effectively in liver transplantation in US Transplant Centers? DRI
1634  2013 Can simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. ED, MED-QoL
1635  2013 Capabilities as menus: a non-welfarist basis for QALY evaluation. ---
1636  2013 Cataract surgery cost utility revisited in 2012: a new economic paradigm. ROI
1637  2013 Cemented, cementless, and hybrid prostheses for total hip replacement: cost effectiveness analysis. ---
1638  2013 Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? ---
1639  2013 Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial). EQ-5D, GORD, SF-36
1640  2013 Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. ATT, BTDB, BTT, CDSR, CE, CENTRAL, CINAHL, CRD, DARE, FDA, HF, HMII, HT, HW, ICERs, IPD, LYG, MM, NHS EED, NLM, QOL, RCTs, UKCRN, VADs
1641  2013 Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model. BIOSIS, CF, CINAHL, CPCI, DPI, HRQoL, RCTs
1642  2013 Common scale valuations across different preference-based measures: estimation using rank data. PBMs
1643  2013 Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service. CI, ICER
1644  2013 Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. HPV
1645  2013 Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. CRC, FIT, FOBT, US
1646  2013 Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. AF, CR
1647  2013 Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. EDSS, GA, JCV, PML, RRMS
1648  2013 Comparison of cost-effectiveness of vitamin D screening with that of universal supplementation in preventing falls in community-dwelling older adults. NMB
1649  2013 Comparison of surveillance strategies for low-risk bladder cancer patients. ---
1650  2013 Comparison of the cost-effectiveness of a high- and a low-intensity smoking cessation intervention in Sweden: a randomized trial. HIT, ICER, LIT, SEK
1651  2013 Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence. ---
1652  2013 Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial. HADS-T, START
1653  2013 Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. BMD, ICER, PMO
1654  2013 Cost effectiveness of high resolution computed tomography with interferon-gamma release assay for tuberculosis contact investigation. CXR, HRCT, QFT, TST
1655  2013 Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. CMM, IDT
1656  2013 Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. CI, CRT, MART, NMBs, NSCLC, RT, VART
1657  2013 Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. OLAI, PLAI, PSA, RLAI
1658  2013 Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland. ITP, IVIG, SOC, TPO-RA
1659  2013 Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome. ACS, ICER, KIF6
1660  2013 Cost effectiveness of the interferon-gamma release assay for tuberculosis screening of hemodialysis patients. BCG, CXR, QFT, TST
1661  2013 Cost effectiveness of the NHS breast screening programme: life table model. ---
1662  2013 Cost effectiveness of tibial nonunion treatment: A comparison between rhBMP-7 and autologous bone graft in two Italian centres. ABG, DRG
1663  2013 Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program. BT-ICT, GDP per capita, ICER, PSA, RI-HSCT
1664  2013 Cost utility of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. ---
1665  2013 Cost utility of hub-and-spoke telestroke networks from societal perspective. ---
1666  2013 Cost--utility analysis of a shock-absorbing floor intervention to prevent injuries from falls in hospital wards for older people. ---
1667  2013 Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. CSDD
1668  2013 Cost-effectiveness analysis of 3-D computerized tomography colonography versus optical colonoscopy for imaging symptomatic gastroenterology patients. LYs, OC
1669  2013 Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. HCV
1670  2013 Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach. MDD, MDEs, QOL, TL
1671  2013 Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. HCV, PR
1672  2013 Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain. CRT, OMT
1673  2013 Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. CLI, IC, PTA
1674  2013 Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. IORT, WB-EBRT
1675  2013 Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. IL28B
1676  2013 Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. ACIP, Td, Tdap
1677  2013 Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. SU, TD
1678  2013 Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. ART
1679  2013 Cost-effectiveness analysis: comparing single-level cervical disc replacement and single-level anterior cervical discectomy and fusion: clinical article. ACDF, CDR, CPT
1680  2013 Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. AOM, ICERs, NTHi, PCVs, PHiD-CV
1681  2013 Cost-effectiveness and economic impact of the KineSpring Knee Implant System in the treatment for knee osteoarthritis. OA
1682  2013 Cost-effectiveness and economic impact of the KineSpring Knee Implant System in the treatment of knee osteoarthritis in Italy. HTO, TKA, UKA
1683  2013 Cost-effectiveness and economic impact of the KineSpring Knee Implant System in the treatment of knee osteoarthritis in the United Kingdom. OA, TKA, UK
1684  2013 Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. LMWHs, NOACs, THR, TKR, VTE
1685  2013 Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. GIST
1686  2013 Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. AOM, IPD, LYG, PNE, SEK
1687  2013 Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study). ICER, WTP
1688  2013 Cost-effectiveness of a helpline for suicide prevention. ---
1689  2013 Cost-effectiveness of a primary care intervention to treat obesity. BLC, CI, EBLC, UC
1690  2013 Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries. CEACs, EQ5D, MCS, SF-36
1691  2013 Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer. FOLFOX, ICER
1692  2013 Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. BMD, ICER, YAM
1693  2013 Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. BRCA, DM, MRI
1694  2013 Cost-effectiveness of alternative thresholds of the fasting plasma glucose test to identify the target population for type 2 diabetes prevention in adults aged ≥45 years. FPG
1695  2013 Cost-effectiveness of an advance notification letter to increase colorectal cancer screening. FOBT, LYG, NBCSP
1696  2013 Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. CINV, ICER
1697  2013 Cost-effectiveness of an improving access to psychological therapies service. IAPT, NICE, RCS
1698  2013 Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system. CRT, HF, ICD, ICER
1699  2013 Cost-effectiveness of cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary artery disease in Germany. CAD, CMR, SPECT
1700  2013 Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. CA, CHD, CMR, ETT, SPECT
1701  2013 Cost-effectiveness of continuous-flow left ventricular assist devices. CI, LVADs, LYG, OMT
1702  2013 Cost-effectiveness of CTA, MRA and DSA in patients with non-traumatic subarachnoid haemorrhage. CTA, DSA, MRA
1703  2013 Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. ---
1704  2013 Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. AF, ICER, INR, RE-LY, SE, VKAs
1705  2013 Cost-effectiveness of depression case management in small practices. DFDs, ICER
1706  2013 Cost-effectiveness of Descemet's stripping endothelial keratoplasty versus penetrating keratoplasty. DSEK, ICERs, logMAR, PK
1707  2013 Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model. AF/AFL, LYG
1708  2013 Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial. BPH, LUTS
1709  2013 Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. ED, EPC, ICER, ORs, QOL
1710  2013 Cost-effectiveness of enzyme replacement therapy for Fabry disease. ERT
1711  2013 Cost-effectiveness of exercise therapy after corticosteroid injection for moderate to severe shoulder pain due to subacromial impingement syndrome: a trial-based analysis. ---
1712  2013 Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. DLBCL, ICERs
1713  2013 Cost-effectiveness of hand-assisted retroperitoneoscopic versus standard laparoscopic donor nephrectomy: a randomized study. HARP, LDN
1714  2013 Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. HBV
1715  2013 Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. AZA, UC
1716  2013 Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. ---
1717  2013 Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. NPH, T2DM
1718  2013 Cost-effectiveness of interferon-gamma release assay for entry tuberculosis screening in prisons. IGRAs, LTBI, QFT, TB, TST
1719  2013 Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. GORD
1720  2013 Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. IGRAs, LTBI, TST
1721  2013 Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. ---
1722  2013 Cost-effectiveness of minimally invasive versus open esophagectomy for esophageal cancer. MIE
1723  2013 Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. BNF, ICER, IR, MR, NHS, RA, TTO
1724  2013 Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. ---
1725  2013 Cost-effectiveness of nutritional intervention in elderly subjects after hip fracture. A randomized controlled trial. ICERs
1726  2013 Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. ICER, UC, ULPSS
1727  2013 Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures. ---
1728  2013 Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. ICERs, PWTM, UC, WTP
1729  2013 Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. ---
1730  2013 Cost-effectiveness of renin-guided treatment of hypertension. HTN, ICER, PRA
1731  2013 Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. ICERs, VTE
1732  2013 Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. AF, NOAC
1733  2013 Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. COPD, LAMA
1734  2013 Cost-effectiveness of screening for chronic hepatitis C infection in the United States. HCV, mCER
1735  2013 Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK. BPH, CombAT, NHS
1736  2013 Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. BCLC, ECOG, HCC, ICER, SOFIA
1737  2013 Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain. CMM, CRPS, EVPI, FBSS, ICER, INMB, PAD, RAP, SCS
1738  2013 Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. CKD, CVD, MI
1739  2013 Cost-effectiveness of supported self-management for CFS/ME patients in primary care. CFS/ME, GP, PR, SL, TAU
1740  2013 Cost-effectiveness of test phase implantation strategies for InterStim sacral neuromodulation. ---
1741  2013 Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. HIV
1742  2013 Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. ACS, ASA, ICER, PLATO
1743  2013 Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. CEA, COPD, POET, SHI, UI
1744  2013 Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ACS, MI, PLATO
1745  2013 Cost-effectiveness of trial of labor after previous cesarean in a minimally biased cohort. ERCD, TOLAC
1746  2013 Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial. ---
1747  2013 Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. ICER
1748  2013 Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. CSDME, WTP
1749  2013 Cost-effectiveness of Xpert MTB/RIF for diagnosing pulmonary tuberculosis in the United States. ICER, TB
1750  2013 Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter? NHS EED, RCTs
1751  2013 Cost-utility analysis of a dance intervention for adolescent girls with internalizing problems. ---
1752  2013 Cost-utility analysis of cataract surgery in Japan: a probabilistic Markov modeling study. CI, ICER
1753  2013 Cost-utility analysis of deferiprone for the treatment of beta-thalassaemia patients with chronic iron overload: a UK perspective. DFO, DFP, DFX, LIC, NHS, QOL, SFC
1754  2013 Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. AEs, ICER, NICE, NSAIDs, WOMAC
1755  2013 Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. CKD, HIV
1756  2013 Cost-utility analysis of minimally invasive versus open multilevel hemilaminectomy for lumbar stenosis. ICER, MIS
1757  2013 Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent beta-thalassemia patients. DFO, DFX
1758  2013 Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. CKD, LPN, LRN, OPN, PN, SRMs
1759  2013 Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis. CI, HRQL
1760  2013 Costs of injury in New Zealand: Accident Compensation Corporation spending, personal spending and quality-adjusted life years lost. ACC, HRQoL
1761  2013 Current methodological issues in the economic assessment of personalized medicine. ---
1762  2013 Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. AF, CU, SD-W
1763  2013 Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity. AWMSG, DCEs
1764  2013 Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. SRE
1765  2013 Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? DMOADs, ICERs, TKR
1766  2013 Do modern total knee replacements offer better value for money? A health economic analysis. QALY, SF-6D
1767  2013 Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. IBD, ICER, VTE
1768  2013 Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation. AF, OAC, TTE
1769  2013 Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease. IC, PTA, SEP
1770  2013 Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. ---
1771  2013 Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. AF, CE, ICER, SA
1772  2013 Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. AAdSS, AIT, AR
1773  2013 Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: a randomized controlled trial. CVD
1774  2013 Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China. ICER, SO
1775  2013 Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. EFV, HAART, RAL, RPV, STR
1776  2013 Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan. CAD, HMG-CoA
1777  2013 Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. CKD-ND, LYG, LYs, NHS
1778  2013 Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression. NMB
1779  2013 Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. UI
1780  2013 Economic evaluation of universal newborn hepatitis B vaccination in China. HBV, HCC
1781  2013 Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. DPP
1782  2013 Effectiveness of active case-finding strategies in tuberculosis control in Kampala, Uganda. ACF, LYS, PCF, TB
1783  2013 Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. ICER, NDO, UI
1784  2013 Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. DR
1785  2013 Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. T1D, T2B-BB, T2D-BOT
1786  2013 Extending contraceptive coverage under the Affordable Care Act saves public funds. ACA
1787  2013 Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. IBD, VTE
1788  2013 Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective. CU, HRQoL, RRT
1789  2013 Gastric bypass is a cost-saving procedure: results from a comprehensive Markov model. BMI
1790  2013 Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. ---
1791  2013 Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. CRC, FIT, FOBT
1792  2013 Helicopter emergency medical services for adults with major trauma. DALYs, GEMS, HEMS, ISS, MTOS, NRS, RCTs, RR, TRISS, WHO
1793  2013 Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. HBV
1794  2013 Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. ---
1795  2013 Immediately sequential bilateral cataract surgery: a cost-effective procedure. CEA, DSBCS, ISBCS
1796  2013 Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. HRQL
1797  2013 Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. JCV
1798  2013 Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study. BHs, MO, OCT
1799  2013 Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients. CKD, ESA, NDD
1800  2013 Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. ---
1801  2013 Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-alpha2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. CC, CHB, ETV, HBeAg, HBsAg, NAs, PEG-IFN, TDF
1802  2013 Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community. ICER, NHS
1803  2013 Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical care trials. ---
1804  2013 Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? NSCLC, OSC, WBRT
1805  2013 Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. UTI
1806  2013 Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model. BC, FFDM, ICER, SFM
1807  2013 Is liver transplantation using organs donated after cardiac death cost-effective or does it decrease waitlist death by increasing recipient death? DBD, DCD, LT
1808  2013 Italian population-based values of EQ-5D health states. ---
1809  2013 Lifestyle Matters for maintenance of health and wellbeing in people aged 65 years and over: study protocol for a randomised controlled trial. ---
1810  2013 Lifetime cost-effectiveness of trial of labor after cesarean in the United States. ERCD, TOLAC
1811  2013 Lifetime costs and outcomes of repair of Tetralogy of Fallot compared to natural progression of the disease: Great Ormond Street Hospital cohort. ACHD, GOSH, UK
1812  2013 Lifetime QALY prioritarianism in priority setting. ---
1813  2013 Long-term health benefits and costs of measurement of carotid intima-media thickness in prevention of coronary heart disease. CHD, CIMT, MI
1814  2013 Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. ART
1815  2013 Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. CP
1816  2013 Management of undescended testis: a decision analysis. UDT
1817  2013 Manual therapy, exercise therapy, or both, in addition to usual care, for osteoarthritis of the hip or knee. 2: economic evaluation alongside a randomized controlled trial. GDP
1818  2013 Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. HTAs
1819  2013 Medical therapy v. PCI in stable coronary artery disease: a cost-effectiveness analysis. BMS, DES, ICER, PCI
1820  2013 Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. ICER, LYG
1821  2013 Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England. SBI
1822  2013 Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. ADAN, GAD, ICER, UC
1823  2013 Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis. 5-FU, LV, mCRC, mFLOX, OS
1824  2013 More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation. DBD, DCD, DGF, PNF, SRTR
1825  2013 Nutritional policy changes in the supplemental nutrition assistance program: a microsimulation and cost-effectiveness analysis. MIs, SNAP, SSBs
1826  2013 Operationalising the capability approach for outcome measurement in mental health research. GAF
1827  2013 Optimizing chronic disease management mega-analysis: economic evaluation. ---
1828  2013 Optimizing the Economic Impact of rtPA Use in a Stroke Belt State: The Case of South Carolina. rt-PA
1829  2013 Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. ER, NOK, PP-LAI
1830  2013 Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. ART, PrEP
1831  2013 Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. BMT, RDN
1832  2013 Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis. ACS, LY, PCI
1833  2013 Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. ACS, PCI
1834  2013 Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis. NHS
1835  2013 Prospective cost-effectiveness analysis of genomic profiling in breast cancer. 70-GS, DDFS
1836  2013 Protons in head-and-neck cancer: bridging the gap of evidence. HNC, IMPT, IMRT, NTCP
1837  2013 Revision lumbar surgery in elderly patients with symptomatic pseudarthrosis, adjacent-segment disease, or same-level recurrent stenosis. Part 2. A cost-effectiveness analysis: clinical article. ASD
1838  2013 Risk Adjustment In Neurocritical care (RAIN)--prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study. EQ-5D-3L, GCS, GOSE, ICER, INB, RAIN, RTAs, TBI
1839  2013 Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. PSA
1840  2013 Routine on-site evaluation of specimen adequacy during initial ultrasound-guided fine needle aspiration of thyroid nodules: a cost-effectiveness analysis. FNA, OSE, QALE
1841  2013 Selection for early surgery in asymptomatic mitral regurgitation: a Markov model. ES, MR, WW
1842  2013 Simulating lifetime outcomes associated with complications for people with type 1 diabetes. CVD, DCCT, LEA
1843  2013 Societal and economic impact of anterior cruciate ligament tears. ACL, MOON
1844  2013 Stratified patient-centered care in type 2 diabetes: a cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness. ICER
1845  2013 Surgical management of traumatic isolated sternal fracture and manubriosternal dislocation. ---
1846  2013 Surgical site infection prevention following total hip arthroplasty in Australia: a cost-effectiveness analysis. AP, AUD, SSI
1847  2013 The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model. ---
1848  2013 The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial. COPD, CRQ, SEPRP
1849  2013 The cost-effectiveness of diagnostic management strategies for children with minor head injury. ---
1850  2013 The cost-effectiveness of mandatory folic acid fortification in Australia. LYG, NTDs, WTP
1851  2013 The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. IBMS, ICER
1852  2013 The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. FXaI, LMWH, THR, TKR, VTE
1853  2013 The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening. CHD
1854  2013 The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. ICD
1855  2013 The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. CEPAC
1856  2013 The cost-effectiveness of shopping to a predetermined grocery list to reduce overweight and obesity. ICERs, SBT
1857  2013 The cost-effectiveness of supervised exercise for the treatment of intermittent claudication. SE, USE
1858  2013 The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. ---
1859  2013 The economic burden of vision loss and eye disorders among the United States population younger than 40 years. ---
1860  2013 The EOS 2D/3D X-ray imaging system: a cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. ---
1861  2013 The health burden and costs of incident fractures attributable to osteoporosis from 2010 to 2050 in Germany--a demographic simulation model. OAF
1862  2013 The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong. AOM, IPD
1863  2013 The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. HCV
1864  2013 The road not taken: transferability issues in multinational trials. CE, RCTs
1865  2013 The societal and economic value of rotator cuff repair. ---
1866  2013 The societal gain of medical development and innovation in gastroenterology. ESR, FIT, HALE
1867  2013 The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. ---
1868  2013 Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. TCF
1869  2013 Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. ---
1870  2013 Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. AEs, LYGs, MET, SAXA, SU
1871  2013 Using a survey to estimate health expectancy and quality-adjusted life expectancy to assess inequalities in health and quality of life. HLE, LE, QALE
1872  2013 Using decision analysis to assess comparative clinical efficacy of surgical treatment of unstable ankle fractures. ---
1873  2013 Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. ---
1874  2013 Validation of a Chinese version of the Quality of Well-Being Scale-Self-Administered (QWB-SA) in patients with epilepsy. AED, HRQoL, ICC, QWB-SA
1875  2013 [Atrial fibrillation in Germany--epidemiology, diagnosis, treatment and costs]. ---
1876  2013 [Cost-effectiveness of an organized breast cancer screening program in Southern Brazil]. ---
1877  2013 [Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia]. PTI
1878  2013 [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening]. ICER, PSA
1879  2014 A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. PML, RRMS
1880  2014 A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation. CHF, EVEREST II HRS, MR
1881  2014 A clinical decision model for selecting the most appropriate therapy for uncomplicated chronic dissections of the descending aorta. chTBADs, CI, OMT, OSR, TEVAR
1882  2014 A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. ASMR, HAS, NICE
1883  2014 A comparison of open and endovascular revascularization for chronic mesenteric ischemia in a clinical decision model. CI, CMI, EV, OR
1884  2014 A cost-effectiveness analysis of a telephone-linked care intervention for individuals with Type 2 diabetes. ---
1885  2014 A cost-utility analysis of a rehabilitation service for people living with and beyond cancer. ICER
1886  2014 A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. CHB, ICER, LYs, NLED, THB
1887  2014 A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. IMRT
1888  2014 A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. ART, CAPRA-S
1889  2014 A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT). CI, KAT, OKS
1890  2014 A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: a comparative cost-effectiveness analysis between international guidelines. AGA, BSG, IBD
1891  2014 Acupuncture in patients suffering from allergic asthma: is it worth additional costs? CI, ICER
1892  2014 An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease. CKD, eGFR, ESRD
1893  2014 Are people consistent when trading time for health? TTO
1894  2014 Assessing outcomes for cost-utility analysis in depression: comparison of five multi-attribute utility instruments with two depression-specific outcome measures. HUI3, MAUI, SF-6D
1895  2014 Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. ICER
1896  2014 Association between lifestyle factors and quality-adjusted life years in the EPIC-NL cohort. ---
1897  2014 Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. ---
1898  2014 Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K. CPAP, NHS, OSA, T2D
1899  2014 Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. IBD, PSC
1900  2014 Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis. CMT, NT, PCNSL
1901  2014 Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure. BTT, HT, HW, LVAD, UK NHS
1902  2014 Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. ACT, MMR-P
1903  2014 Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. ART, PrEP
1904  2014 Comparative effectiveness of treatment options for pediatric craniopharyngiomas. GTR
1905  2014 Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder. MDD
1906  2014 Coronary bypass surgery versus percutaneous coronary intervention: cost-effectiveness in Iran: a study in patients with multivessel coronary artery disease. CABG, HRQoL, LYs, PCI
1907  2014 Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. AASLD, CHC, IDSA, IFN, SOF/RBV, SOF/SMV, SVR
1908  2014 Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. OD, UC
1909  2014 Cost effectiveness analysis of a next generation risk assessment score for cardiovascular disease. MESA
1910  2014 Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer. ICERs, SEER
1911  2014 Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease. GES, ICERs, MPI, OCAD, US
1912  2014 Cost effectiveness of a novel 10 kHz high-frequency spinal cord stimulation system in patients with failed back surgery syndrome (FBSS). CMM, FBSS, ICER, SCS
1913  2014 Cost effectiveness of a survivorship care plan for breast cancer survivors. PCP, RCT, SCPs
1914  2014 Cost effectiveness of adding dapagliflozin to insulin for the treatment of type2 diabetes mellitus in the Netherlands. LYs, T2DM
1915  2014 Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. AF, ICERs, VKAs
1916  2014 Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. ---
1917  2014 Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective. AEs, ICERs, NICE, NSAIDs, OA
1918  2014 Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. CCO NDFP, ICER, NSCLC
1919  2014 Cost effectiveness of eplerenone in patients with chronic heart failure. AR-DRG, CHF, NYHA
1920  2014 Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. ER, OAB, UUI
1921  2014 Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial. DAFNE, ICC
1922  2014 Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries. HIV, ICER, IGRAs, QFT, TB, TST
1923  2014 Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. ER, LYs, NNBC
1924  2014 Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. ICERs
1925  2014 Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting beta-agonists. ICSs, LABAs, NHS
1926  2014 Cost effectiveness of training rural providers to perform joint injections. CBOCs, VA
1927  2014 Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes. MHs, PPV, VMAs
1928  2014 Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites. CI, DBS, GPi, PD, STN, VA
1929  2014 Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands. BPR, MTC, PR, SVR, TE, TN, TPR
1930  2014 Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. HBsAg, HBV, ICER, NNDRS
1931  2014 Cost-effectiveness analysis of acupuncture, counselling and usual care in treating patients with depression: the results of the ACUDep trial. ACUDep, ICER
1932  2014 Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. ICERs
1933  2014 Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood. HRQoL, ICER
1934  2014 Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. ---
1935  2014 Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand. HALYs, ICER, PPP, WTP
1936  2014 Cost-Effectiveness Analysis of Early Reconstruction Versus Rehabilitation and Delayed Reconstruction for Anterior Cruciate Ligament Tears. ACL, ACLR, DR, ER, KOOS, MOON, SF-6D
1937  2014 Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. ASCT, dASCT, eASCT, MM, OS
1938  2014 Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. BC, CE, Extended AI, ICERs, SA
1939  2014 Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. ICERs, VTE
1940  2014 Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. HLA, SJS, TEN
1941  2014 Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals. ICUR
1942  2014 Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs. DALYs, MDR-TB
1943  2014 Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. ---
1944  2014 Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesions. BA, OAS
1945  2014 Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. ICERs, RR, UC
1946  2014 Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. TAPS
1947  2014 Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. ICER, QIV, TIV
1948  2014 Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. ---
1949  2014 Cost-effectiveness analysis of the national Perinatal Hepatitis B Prevention Program. HepB, PHBPP
1950  2014 Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. CDI, FMT, ICER, RCDI
1951  2014 Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. ICER
1952  2014 Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. FFP, SD
1953  2014 Cost-effectiveness and cost-utility of a Web-based or print-delivered tailored intervention to promote physical activity among adults aged over fifty: an economic evaluation of the Active Plus intervention. PA, PB, PE, WB, WE
1954  2014 Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. HPV, ICER, NZ
1955  2014 Cost-effectiveness comparison between topical silver sulfadiazine and enclosed silver dressing for partial-thickness burn treatment. SSD
1956  2014 Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer. base case, ICER
1957  2014 Cost-effectiveness of a community-based physical activity programme for adults (Be Active) in the UK: an economic analysis within a natural experiment. ---
1958  2014 Cost-effectiveness of a universal strategy of brief dietary intervention for primary prevention in primary care: population-based cohort study and Markov model. ---
1959  2014 Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. ICER, PFS, QOL
1960  2014 Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. AF, ICERs
1961  2014 Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. AF, VKA
1962  2014 Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. BPD, CHDs, EPS, MOH
1963  2014 Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. BD-I
1964  2014 Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. CATT
1965  2014 Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. PCR, RBC, TTB, UDHQ
1966  2014 Cost-effectiveness of cervical total disc replacement vs fusion for the treatment of 2-level symptomatic degenerative disc disease. ACDF, CTDR, RCT
1967  2014 Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus. EAC, PPIs
1968  2014 Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. TIA
1969  2014 Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. CBT
1970  2014 Cost-effectiveness of collaborative care for depression in UK primary care: economic evaluation of a randomised controlled trial (CADET). CADET, CEAC, ICER
1971  2014 Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer. ICER
1972  2014 Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border. DCEM
1973  2014 Cost-effectiveness of computer-tailored smoking cessation advice in primary care: a randomized trial (ESCAPE). ESCAPE, ICER
1974  2014 Cost-effectiveness of cranberry capsules to prevent urinary tract infection in long-term care facilities: economic evaluation with a randomized controlled trial. LTCF, UTI
1975  2014 Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. AAD, PAF
1976  2014 Cost-effectiveness of CT screening in the National Lung Screening Trial. CI, CT, ICERs, NLST
1977  2014 Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. AF, ICERs
1978  2014 Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. AF, ICH, INR
1979  2014 Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States. ICER
1980  2014 Cost-effectiveness of early laparoscopic cholecystectomy for mild acute gallstone pancreatitis. ---
1981  2014 Cost-effectiveness of early-initiated treatment for advanced-stage epithelial ovarian cancer patients: a modeling study. EOC
1982  2014 Cost-effectiveness of endovascular versus open repair of acute complicated type B aortic dissections. OR, TEVAR
1983  2014 Cost-effectiveness of ensuring hepatitis B protection for previously vaccinated healthcare personnel. HCP, ICERs
1984  2014 Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. HF
1985  2014 Cost-effectiveness of febuxostat in chronic gout. ICER, SMC, SUA
1986  2014 Cost-effectiveness of femtosecond laser-assisted cataract surgery versus phacoemulsification cataract surgery. CEA, ICERs, LCS, PCS
1987  2014 Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. ICER
1988  2014 Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ACS, ICERs
1989  2014 Cost-effectiveness of hepatitis A vaccination in Indonesia. GDP, ICER
1990  2014 Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel. ---
1991  2014 Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program. BTDB, BTT, ICER, LVADs
1992  2014 Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. MR, MRGB, MRI, PCa, QOL, TRUS-GB
1993  2014 Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. AEs, ICER
1994  2014 Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. ICER
1995  2014 Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. NAC, RC
1996  2014 Cost-effectiveness of osteo-odonto keratoprosthesis in Singapore. OOKP
1997  2014 Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants. AD, SF
1998  2014 Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom. mSTS, OS, PFS
1999  2014 Cost-Effectiveness of Periodontitis Management in Public Sector Specialist Periodontal Clinics: A Societal Perspective Research in Malaysia. CALs, MYR
2000  2014 Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry. CI, ICD, ICER, LYs
2001  2014 Cost-effectiveness of questionnaires in preventing transfusion-transmitted infections. BE, DHQ, ICER, TTIs
2002  2014 Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. nAMD, NHS
2003  2014 Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris. ICER, SAQAF, SOC
2004  2014 Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. LYG
2005  2014 Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. DVT, PE, VKA, VTE
2006  2014 Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. AF, ICERs
2007  2014 Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. CATIE, CLZ, ICER, OLZ, QTP, RSP, SGAs, ZSD
2008  2014 Cost-effectiveness of silicone and alginate impressions for complete dentures. ---
2009  2014 Cost-effectiveness of specialized treatment based on cognitive behavioral therapy versus usual care for tinnitus. BCI
2010  2014 Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. ACIP, Tdap
2011  2014 Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. HCV, PR, SVR, TVR, US
2012  2014 Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. HBeAg, HBsAg, HBV
2013  2014 Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. ACE, ALVD, COG, ICERs
2014  2014 Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. ---
2015  2014 Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation. ---
2016  2014 Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. ICER, TIMS-China, tPA
2017  2014 Cost-effectiveness of total disc replacement versus multidisciplinary rehabilitation in patients with chronic low back pain: a Norwegian multicenter RCT. CLBP, EQ-5D, MDR, SF-6D, TDR
2018  2014 Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures. ---
2019  2014 Cost-effectiveness of treatment of diabetic macular edema. DME, ICERs, VEGF
2020  2014 Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. ICER
2021  2014 Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. CARDERA
2022  2014 Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial. EVLA, UGFS
2023  2014 Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study. ICERs
2024  2014 Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. CG, COPD, ICER, TG
2025  2014 Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. 5-FU, ICER, SEER
2026  2014 Cost-utility analysis of gastric bypass for severely obese patients in Spain. ---
2027  2014 Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. ACS, ICURs, MI, PCI
2028  2014 Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. BMI, DPP-4, GLP-1, NPH, SEK, T2DM, WTP
2029  2014 Cost-utility analysis of individual psychosocial support interventions for breast cancer patients in a randomized controlled study. INS, SC
2030  2014 Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand. NOACs, SPAF
2031  2014 Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. ICERs
2032  2014 Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia. CN, ICERs, RAAS-I, WTP
2033  2014 Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer. CSG, ICER, LYs, NCCN, SOG
2034  2014 Cost-utility analysis of treatments for stage IB cervical cancer. CCRT, RHPLND
2035  2014 Costs and cost-effectiveness of periviable care. ---
2036  2014 Decision analysis model of open repair versus endovascular treatment in patients with asymptomatic popliteal artery aneurysms. aPAAs, CI, GSVB, OMT
2037  2014 Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. mOP, PMO
2038  2014 Depression in working adults: comparing the costs and health outcomes of working when ill. ---
2039  2014 Developing Effective and Efficient care pathways in chronic Pain: DEEP study protocol. ---
2040  2014 Disease-outcome trees, EQ-5D scores, and estimated annual losses of quality-adjusted life years (QALYs) for 14 foodborne pathogens in the United States. ---
2041  2014 Dynamic medication adherence modeling in primary prevention of cardiovascular disease: a Markov microsimulation methods application. CV
2042  2014 Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany. AVDs, BSC, RP
2043  2014 Early psychosocial intervention in Alzheimer's disease: cost utility evaluation alongside the Danish Alzheimer's Intervention Study (DAISY). DAISY
2044  2014 Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. CINV, GDP, HEC
2045  2014 Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. ---
2046  2014 Economic effects of treatment of chronic kidney disease with low-protein diet. CKD
2047  2014 Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. BIA, HCC, ICER, LYs, US, WTP
2048  2014 Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty. ---
2049  2014 Economic evaluation of brief psychodynamic interpersonal therapy in patients with multisomatoform disorder. ICER, LOCF, PIT
2050  2014 Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence. PSA, UI
2051  2014 Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. MenB
2052  2014 Economic evaluation of nurse-led intensive care follow-up programmes compared with standard care: the PRaCTICaL trial. CI, ICU
2053  2014 Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. AML, IFI, MDS, PSA, SEK
2054  2014 Economic evaluation of surgical insertion of ventilation tubes for the management of persistent bilateral otitis media with effusion in children. EVPI, HAs, OME, VTs
2055  2014 Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood. ALL, BFM, DFCI, HRQL
2056  2014 Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. CLL
2057  2014 Effect of adding a sleep dimension to the EQ-5D descriptive system: a "bolt-on" experiment. GPBMs, TTO
2058  2014 Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. HbA1c
2059  2014 Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. ART, IDUs, MMT
2060  2014 Effectiveness and cost-effectiveness of an awareness campaign for colorectal cancer: a mathematical modeling study. CRC
2061  2014 Endovascular vs. open repair of complicated acute type B aortic dissections. cABAD, CI, OSR, TEVAR
2062  2014 Epidemiology and economic burden of osteoporosis in Switzerland. ---
2063  2014 Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. CDSR, CENTRAL, CiC, CIs, DARE, EGFR-TK, EGFR-TKIs, HTA, NSCLC, PCR, SCI
2064  2014 Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. ---
2065  2014 Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes. IRR, NMB
2066  2014 Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. AIT, ARC, OR
2067  2014 Estimation of life expectancy and quality-adjusted life expectancy in non-metastatic nasopharyngeal cancer patients treated by intensity-modulated radiotherapy with or without chemotherapy. EORTC, IMRT, LE, NPC, QALE, QOL
2068  2014 Exercise-based rehabilitation for heart failure. CENTRAL, CI, HF, RR
2069  2014 Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom. ART, MSM, PLHIV, PWID, UK
2070  2014 FDA's proposed ban on trans fats: How do the costs and benefits stack up? ---
2071  2014 Health economic evaluation of single-lead atrial pacing vs. dual-chamber pacing in sick sinus syndrome. AAIR, WTP
2072  2014 Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany. IA, MVE, NNT, RHI
2073  2014 Health-related quality of life after myocardial infarction, does choice of method make a difference? HRQoL, SF, STEMI
2074  2014 Health-related utility values of patients with primary Sjogren's syndrome and its predictors. EQ-5D, pSS
2075  2014 Hip arthroscopy for femoroacetabular impingement: a health economic analysis. SF12-6D
2076  2014 Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. CHD, HRT, RCT
2077  2014 Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care: population-based cohort study and Markov model. ---
2078  2014 Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. DAA, IFN, RBV, SVR
2079  2014 Impact of short periods with worsened or improved INR control on life expectancy and QALYs in patients with atrial fibrillation. AF, INR, SDTINR, TTR
2080  2014 Impact of the National Breast and Cervical Cancer Early Detection Program on cervical cancer mortality among uninsured low-income women in the U.S., 1991-2007. LYs, NBCCEDP
2081  2014 Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. CVEs, MIs
2082  2014 Improving the quality of percutaneous revascularisation in patients with multivessel disease in Australia: cost-effectiveness, public health implications, and budget impact of FFR-guided PCI. ANGIO, FFR, PCI
2083  2014 Inclusiveness in the health economic evaluation space. ---
2084  2014 Increasing access to specialty surgical care: application of a new resource allocation model to bariatric surgery. ---
2085  2014 Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery. ASD, CEAC, HRQoL, ICER
2086  2014 Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan? ICERs, NHI, NHIS
2087  2014 Is antibiotic prophylaxis necessary before midurethral sling procedures for female stress incontinence? A decision analysis. MID, MUS, RCT
2088  2014 Is brief advice in primary care a cost-effective way to promote physical activity? BA, ICER, PA
2089  2014 Is dietetic treatment for undernutrition in older individuals in primary care cost-effective? ICER, ICUR
2090  2014 Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. HPV
2091  2014 Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. BC, PSA
2092  2014 Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden. ICER, LOH, TRT, TU
2093  2014 Lifetime QALY prioritarianism in priority setting: quantification of the inherent trade-off. CEA
2094  2014 Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. DES, LYs, OLAI, RLAI
2095  2014 Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand. ICER
2096  2014 Long-term cost-effectiveness analysis of endovascular versus open repair for abdominal aortic aneurysm based on four randomized clinical trials. AAA, EVAR
2097  2014 Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial. ICERs, MET, PA
2098  2014 Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. WOSCOPS
2099  2014 Making use of equity sensitive QALYs: a case study on identifying the worse off across diseases. ---
2100  2014 Medical decision analysis for first-line therapy of chronic myeloid leukemia. CML, LYs, TKIs
2101  2014 Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination. ---
2102  2014 Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity. AMD, anti-VEGF
2103  2014 Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. CLL, QALYG, R-FC
2104  2014 Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. ICERs
2105  2014 MRI-guided focused ultrasound surgery for uterine fibroid treatment: a cost-effectiveness analysis. ICER, UAE, WTP
2106  2014 Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. CI, FFA, nAMD, OCT, SD-OCT, TD-OCT
2107  2014 Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers. ILI
2108  2014 Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. PAS
2109  2014 Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer. CE, ICRs, QART
2110  2014 Pan computed tomography versus selective computed tomography in stable, young adults after blunt trauma with moderate mechanism: a cost-utility analysis. PCT, RIC, SCT
2111  2014 Pediatric intracranial arachnoid cysts: comparative effectiveness of surgical treatment options. ---
2112  2014 Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective. ESRD, PD
2113  2014 Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. s.c, THR, TKR, VTE
2114  2014 Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. HAL-LAI, LAI, PP-LAI, SEK
2115  2014 Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective? DMOADs, ICERs, OA, OAPol, QALE
2116  2014 Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. CHB, HBeAg, HBsAg, HCC, ICERs
2117  2014 Population-level cost-effectiveness of implementing evidence-based practices into routine care. MPRs
2118  2014 Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. HPV
2119  2014 Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. BP, TDM
2120  2014 Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. CrI
2121  2014 Predicting health utilities for children with autism spectrum disorders. ASDs, HUI3
2122  2014 Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: a cost-effectiveness analysis. PD
2123  2014 Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective? GBS, IAP
2124  2014 Prices need no preferences: social trends determine decisions in experimental markets for pain relief. DALYs
2125  2014 QALY as evaluation tool in a health surveillance program. HRQL, RLE
2126  2014 Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds. CI, IQR, POCTs, RCT, RSV, RT-PCR
2127  2014 Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. cDMARDs, CI, DAS28, DMARDs, EQ-5D, HAQ, RA, TACIT, TNFis
2128  2014 Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. ---
2129  2014 Responsiveness of the EQ-5D to clinical change: is the patient experience adequately represented? acne
2130  2014 Rhegmatogenous retinal detachment surgery in elderly people over 70 years old: visual acuity, quality of life, and cost-utility values. BCVA, CNY, logMAR, RRD
2131  2014 Second-line agents for glycemic control for type 2 diabetes: are newer agents better? LYs
2132  2014 Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan. ---
2133  2014 Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. HCV
2134  2014 START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia. CI, HADS-A, HADS-D, HADS-T, HSQ, OR, QOL, QOL-AD, START, TAU
2135  2014 Strategic planning to reduce the burden of stroke among veterans: using simulation modeling to inform decision making. ---
2136  2014 Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation - the CASCADE study. CI, NICE, QOL, T1D
2137  2014 Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status. QOL
2138  2014 Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy. BIOSIS, CE CMR, CI, CMR, PET, SPECT
2139  2014 Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis. ---
2140  2014 That's what friends are for: adolescent peer social status, health-related quality of life and healthcare costs. NMB
2141  2014 The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis. LYG
2142  2014 The agreement between proxy and self-completed EQ-5D for care home residents was better for index scores than individual domains. ICC
2143  2014 The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis. CCC, CT, MRI, SOL
2144  2014 The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study. CRC
2145  2014 The cost effectiveness of acellular dermal matrix in expander-implant immediate breast reconstruction. ADM, ICUR
2146  2014 The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. CF, DPI, FEV1, ICER, NHS, PAS, PSS
2147  2014 The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective. HF, SHIfT
2148  2014 The cost-effectiveness analysis of video capsule endoscopy compared to other strategies to manage acute upper gastrointestinal hemorrhage in the ED. EDs, GI
2149  2014 The cost-effectiveness of school-based eating disorder screening. CI, ED
2150  2014 The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: insights from the US and Korean healthcare systems. ---
2151  2014 The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. ICERs, RP
2152  2014 The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. ---
2153  2014 The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations. CVZ, HMII, HTA, LVADs, LYG, NHS EED, OMT, QOL
2154  2014 The economic burden of disease by industry: Differences in quality-adjusted life years and associated costs. NHIS, NORA
2155  2014 The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. ChEI
2156  2014 The incidence and implications of cerebral palsy following potentially avoidable obstetric complications: a preliminary burden of disease study. QOL
2157  2014 The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension. ---
2158  2014 The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study. HCV, IDUs
2159  2014 The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system. FLS, ICER
2160  2014 The potential of the Child Health Utility 9D Index as an outcome measure for child dental health. CHU9D, CPQ, DMFT, HRQoL, OHRQoL
2161  2014 Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulation after conservative therapy for the management of fecal incontinence. CT, FI, IFDs, SNS
2162  2014 Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. ACS, PLATO
2163  2014 Tobacco control policies specified according to socioeconomic status: health disparities and cost-effectiveness. SES
2164  2014 Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. IIP, IPF, NHS
2165  2014 Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers. ---
2166  2014 Valuing vaccines using value of statistical life measures. DALYs, VSL
2167  2014 VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model. CI, HR, MTC, NIHR, RCT, VenUS IV
2168  2014 Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach. EMOT, HRQoL, OS, PHYS, VEST
2169  2014 What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. LYs, NICE
2170  2014 Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. CVD
2171  2014 Withdrawal of immunosuppression following pediatric liver transplantation: a Markov analysis. ---
2172  2014 [Assessing Chinese herbal medicines for benefiting qi and activating blood circulation in treating unstable angina based on Markov model: a long-term clinical effectiveness exploration]. CHMBQABC, PCI, QDBSS, UA
2173  2015 A comparison of the cost-effectiveness of two pedometer-based telephone coaching programs for people with cardiac disease. CR
2174  2015 A Cost-Effectiveness Analysis of Surgery for Middle-Aged Men with Severe Obstructive Sleep Apnea Intolerant of CPAP. CPAP, CPAP-PPRS, ICER, MLS, OSA, PPRS
2175  2015 A Cost-effectiveness Analysis of Surgery, Endothermal Ablation, Ultrasound-guided Foam Sclerotherapy and Compression Stockings for Symptomatic Varicose Veins. CS, ETA, GDG, NMA, UGFS
2176  2015 A cost-effectiveness analysis of the first federally funded antismoking campaign. LYs, Tips
2177  2015 A Cost-Effectiveness Analysis of the Swedish Universal Parenting Program All Children in Focus. ---
2178  2015 A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. ---
2179  2015 A cost-utility analysis of laparoscopic radical prostatectomy and robotic-assisted laparoscopic radical prostatectomy in men with localized prostate cancer in Thailand. ICER, WTP
2180  2015 A Cost-Utility Analysis of Lumbar Decompression With and Without Fusion for Degenerative Spine Disease in the Elderly. ---
2181  2015 A cost-utility analysis of sacral anterior root stimulation (SARS) compared with medical treatment in patients with complete spinal cord injury with a neurogenic bladder. EVPI, SARS
2182  2015 A decade of investment in infection prevention: a cost-effectiveness analysis. CLABSI, HAI, ICERs, ICUs, LYs, VAP
2183  2015 A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults. BMI, CI, MI, OR, RCT, WLM
2184  2015 A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. AF, ESC, GTS
2185  2015 A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers. MDP, PM, PO
2186  2015 A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. H-BSO, HRQoL, IHC, MSI
2187  2015 A model-based cost-effectiveness analysis of a grommets-led care pathway for children with cleft palate affected by otitis media with effusion. OME
2188  2015 A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT. BSC, CI, CPAP, EQ-5D, ESS, NIHR, OSAS
2189  2015 A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly. aTIV, QIV, TIV
2190  2015 A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. CI, EQ-5D, HMB, LNG-IUS, MMAS, QOL, SF-6D
2191  2015 A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). BCVA, CI, ETDRS, GA, GMR, IVAN, nAMD, OR
2192  2015 A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. CHD,